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Figure 1

* In some experiments, HPV episomal copy number was reduced to
undetectable levels at concentrations of polyamide as low as 5uM (Q-PCR;
200ng input DNA).
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Figure 3

* In some experiments, HPV episomal copy number was reduced to
undetectable levels at concentrations of polyamide as low as 5uM (Q-PCR:
200ng input DNA).
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1.
COMPOUNDS FORTREATING PAPLLOMA
VIRUS INFECTION
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH ORDEVELOPMENT

5

This invention was developed, in part, with government
funding under Grant Numbers R41AI062182,
R41AI068159, R42AI062182 and R42AI068159 awarded by

10

the National Institutes of Health. The United States Govern

ment may have certain rights in this invention.
CROSS-REFERENCE TO RELATED
APPLICATIONS
15

This application is a continuation-in-part of U.S. patent
application Ser. No. 12/534,693, filed on Aug. 3, 2009, now

the most successful treatment on the market. An effective,

specific HPV treatment has the potential to significantly
improve upon, and effectively compete with, Imiquimod.
The majority of human cervical carcinomas (95%) contain
and express HPV DNA and it is the expression of two viral
oncoproteins, E6 and E7, that appears to be critical for cellu

U.S. Pat. No. 8,119,677, which is a continuation of U.S.

patent application Ser. No. 1 1/800,105 filed on May 4, 2007,
now U.S. Pat. No. 7,589,171, which is a continuation of PCT

Application No. PCT/US 07/06133, filed on Mar. 9, 2007 and
claims the benefit of U.S. Provisional application No. 60/797,
426 filed on May 4, 2006, each of which is herein incorpo
rated in its entirety by reference for all purposes.

lar transformation and maintenance of the transformed State.
25

perhaps twenty percent (20%) of all cancer deaths in women
worldwide are from cancers that are associated with HPV.
30

35

TECHNICAL FIELD OF THE INVENTION

The present invention relates to polyamide compositions
and therapies for treatment of cells infected with human pap
illoma virus (HPV).

40

Generally speaking, HPVs are grouped into types based on
the uniqueness of their DNA sequence.
HPVs can be further classified as either high or low risk on
the basis of the clinical lesions with which they are associated
and the relative propensity for these lesions to progress to
cancer. Low risk types, such as HPV types HPV-1, HPV-2,
HPV-3, HPV-4, HPV-5, HPV-7, HPV-8, and HPV-9 cause

common warts (verrucae Vulgaris), plantar warts (verrucae
plantaris), mosaic warts, flat warts (verrucae plane), and
butcher warts. Furthermore, HPV types HPV-6 and HPV-11
cause warts of the external genitalia, anus and cervix. High
risk types, such as HPV-16, HPV-31, HPV-33 and HPV-45 are
particularly common in intraepithelial carcinomas, neopla
sias and cancers. In particular, the genomes of two HPV
types, HPV-16 and HPV-18, have been found to be associated
with about 70% of invasive carcinomas of the uterine cervix.

BACKGROUND OF THE INVENTION
45

Human papilloma virus is a small double-stranded DNA
virus that colonizes various stratified epithelia like skin, oral
and genital mucosa, and induces the formation of self-limit
ing benign tumors known as papillomas (warts) or condylo
mas. Most of these benign tumors naturally regress due to the
influence of host immunological defenses. Some HPVs, how
ever, have oncogenic potential and have been associated with
certain types of cancers. See, Lorincz et al., Obstetrics &
Gynecology, 79:328-337 (1992); Beaudenon et al., Nature,
321:246-249 (1986); and Holloway et al., Gynecol. Onc.,
41:123-128 (1991).
HPV is the most prevalent, sexually transmitted virus.
More than 35 HPV genotypes are known to be sexually trans
mitted, but a relatively few genotypes account for the major
ity of ano-genital infections. Among these most common
HPV types are two forms with high risk for carcinogenic
progression (HPV 16 and HPV 18), and two forms that cause
the majority of genital warts (HPV6 and HPV11).
An estimated 5.5 million people become infected with
HPV each year in the United States, and an estimated 20
million Americans are currently infected (Cates and et al.,
Lancet, 354, Suppl. SIV62, 1999). Approximately 75 percent

Specifically, four HPV types (HPV 16, HPV-18, HPV-31, and
HPV-45) have been connected to 75-93% of the cases of
cervical cancer in the United States. It has been estimated that

INCORPORATION-BY-REFERENCE OF
INFORMATION SUBMITTED
ELECTRONICALLY

The Sequence Listing, which is a part of the present dis
closure, includes a computer readable file “5015679
13 ST25.TXT generated by U.S. Patent & Trademark
Office PatentIn version 3.5 software comprising nucleotide
and/or amino acid sequences of the present invention. The
Subject matter of the Sequence Listing is incorporated herein
by reference in its entirety.

2
of the male and female reproductive-age population has been
infected with sexually transmitted HPV, though the main
public health risk is to women through cervical cancer (Kout
sky, Am. J. Med., 102(5A), 3-8, 1997). Thus, millions of
people in the U.S. alone require treatment each year. It’s
important to note that PAP smears represent the largest public
health Screening program in the world, and that the test is,
essentially, a measure of HPV infection. The current standard
for managing a positive PAPSmear is “follow up. In general,
no treatment is recommended unless an advanced Stage of
cervical dysplasia is observed (CDC Sexually Transmitted
Diseases Treatment Guidelines, 2002).
Significant need exists in HPV positive patients for effec
tive HPV antiviral drugs. At present no specific treatments
exist for HPV or warts. AldaraTM (Imiquimod), a non-specific
immunomodulator used for treating external genital warts, is

Current treatment for HPV infection is extremely limited.
Management normally involves physical destruction of the
wart by Surgical, cryoSurgical, chemical, or laser removal of
infected tissue. Some of these current treatments, like laser

50
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removal and Surgery, are expensive and require the use of
anesthesia to numb the area to be treated. CryoSurgical
removal requires the use of special equipment. Furthermore,
most patients experience moderate pain during and after the
procedure.
Topical creams and solutions such as preparations of
5-fluorouracil, imiquimod, cidofovir, formaldehyde, glutaral,
cimetidine, trichloroacetic acid, bleomycin, podofilox and
podophyllum preparations have also been used. (Reichman in
Harrison's 7 Principles of Internal Medicine, 13th Ed. (Issel
bacher et al., eds.): McGraw-Hill, Inc., NY (1993) pp. 801
803). Recurrence after these treatments, however, is common,
most likely due to the fact that the virus remains latent within
the skin cells. Therefore, subsequent repetitive treatments
must be used, which can destroy healthy tissue. These treat
ments are not available or approved for treatment of cervical
infections.
Interferon has so far been the most effective treatment for

HPV, however, its effectiveness is limited. (Chang et al.

US 8,993,609 B2
3
(2002) Journal of Virology 76: 8864-74, found some cells
infected with HPV genomes became resistant to interferon
treatment after only a few applications). See also Cowsert
(1994) Intervirol. 37:226-230; Bornsteinet al. (1993) Obstet
rics Gynecol. Sur. 4504:252-260; Browder et al. (1992) Ann.

4
the pharmaceutical composition comprising a pharmaceuti
cally acceptable carrier and a compound of formula
5

Pharmacother. 26:42-45.

There is a need for therapeutics for treating a number of
diseases and conditions as outlined in this application.
SUMMARY OF THE INVENTION

10

The present invention provides polyamides, polyamide
compositions, and methods for treating HPV infected cells. In
Some embodiments, the polyamide antiviral agents are well
Suited for treating laryngeal papillomatosis, cervical dyspla
sia and cancer and recurrent respiratory papillomatosis
(RRP).
In another embodiment, the present invention includes a
compound of the formula

15

or a pharmaceutically acceptable salt thereof, wherein: m+3
is at least 11; n m-o: o is 0, 1 or 2; Z is desamino-imidazole

(Formula V. Im); X may independently be 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-meth
ylpyrrole (P) or B-alanine (B): Y may be y-aminobutyric acid
(Y), (S)-2,4-diaminobutyric acid, (R)-2,4-diaminobutyric
acid (formula VI), (S)-2-(acetylamino)-4-aminobutyric acid,
(R)-2-(acetylamino)-4-aminobutyric acid (Y);Y may be
B-alanine or a bond, with the proviso that when Y is a bond
then m+3 is at least 12; and A may be 3,3'-diamino-N-meth
yldipropylamine (Ta) or dimethylaminopropylamine (Dp). In
various embodiments, m may be an integer between 8 and 11
and n may be an integer between 6 and 10. In various embodi
ments, the compounds have an ICs of less than about 1.0LM
or an ICs of less than about 0.1 uM in inhibiting HPV-16
growth in culture. In various embodiments, the compounds
are designed to bind to HPV-16. In various embodiments, the
compounds are designed to bind to HPV-16 DNA. In various
embodiments, the compounds are designed to bind to a
double stranded DNA comprising SEQ ID NO:1 and its
complement (SEQID NO:2).
In another embodiment, the compound has the formula
or a pharmaceutically acceptable salt thereof, wherein m+3 is

25

is at least 11; n m-o: o is 0, 1 or 2; Z is desamino-imidazole

(Formula V. Im); X may independently be 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-meth
ylpyrrole (P) or B-alanine (B): Y may bey-aminobutyric acid
(Y), (S)-2,4-diaminobutyric acid, (R)-2,4-diaminobutyric
acid (formula VI), (S)-2-(acetylamino)-4-aminobutyric acid,
(R)-2-(acetylamino)-4-aminobutyric acid (Y);Y may be
B-alanine or a bond, with the proviso that when Y is a bond
then m+3 is at least 12; and A may be 3,3'-diamino-N-meth
yldipropylamine (Ta) or dimethylaminopropylamine (Dp). In
various embodiments, m may be an integer between 8 and 11
and n may be an integer between 6 and 10. In various embodi
ments, the compounds have an ICso of less than about 1.0LM
or an ICs of less than about 0.1 uM in inhibiting HPV-16
growth in culture. In various embodiments, the compounds
are designed to bind to HPV-16. In various embodiments, the
compounds are designed to bind to HPV-16 DNA. In various
embodiments, the compounds are designed to bind to a
double stranded DNA comprising SEQ ID NO:1 and its
complement (SEQ ID NO:2).
In another embodiment, the present invention includes a
pharmaceutical composition for treating HPV-16 in a patient,
the pharmaceutical composition comprising a pharmaceuti
cally acceptable carrier and a compound of formula

30

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 8: n-m-o: o is 0, 1 or 2; Z is desamino-imidazole
35

40

45

at least 8: n-m-o: o is 0, 1 or 2; Z is desamino-imidazole

(Formula V. Im); X may independently be 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-meth
ylpyrrole (P) or B-alanine (B): Y may be y-aminobutyric acid
(Y), (S)-2,4-diaminobutyric acid, (R)-2,4-diaminobutyric
acid (formula VI), (S)-2-(acetylamino)-4-aminobutyric acid,
or (R)-2-(acetylamino)-4-aminobutyric acid (Y); Y may
be f3-alanine or a bond, with the proviso that when Y is a bond
then m+3 is at least 9; and A may be 3,3'-diamino-N-methyl
dipropylamine (Ta) or dimethylaminopropylamine (Dp). In
various embodiments, m may be an integer between 5 and 8
and n may be an integer between 3 and 7. In various embodi
ments, the compounds have an ICso of less than about 1.0LM
or an ICs of less than about 0.1 uM in inhibiting HPV-16
growth in culture. In various embodiments, the compounds
are designed to bind to HPV-16. In various embodiments, the
compounds are designed to bind to HPV-16 DNA. In various
embodiments, the compounds are designed to bind to a
double stranded DNA comprising SEQ ID NO:1 and its
complement (SEQID NO:2).
In another embodiment, the present invention includes a
pharmaceutical composition for treating HPV-16 in a patient,

or a pharmaceutically acceptable salt thereof, wherein: m+3

50

(Formula V. Im); X may independently be 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-meth
ylpyrrole (P) or B-alanine (B): Y may bey-aminobutyric acid
(Y), (S)-2,4-diaminobutyric acid, (R)-2,4-diaminobutyric
acid (formula VI), (S)-2-(acetylamino)-4-aminobutyric acid,
or (R)-2-(acetylamino)-4-aminobutyric acid (Y); Y may
be f3-alanine or a bond, with the proviso that when Y is a bond
then m+3 is at least 9; and A may be 3,3'-diamino-N-methyl
dipropylamine (Ta) or dimethylaminopropylamine (Dp). In
various embodiments, m may be an integer between 5 and 8
and n may be an integer between 3 and 7. In various embodi
ments, the compounds have an ICso of less than about 1.0LM
or an ICs of less than about 0.1 uM in inhibiting HPV-16
growth in culture. In various embodiments, the compounds
are designed to bind to HPV-16. In various embodiments, the
compounds are designed to bind to HPV-16 DNA. In various
embodiments, the compounds are designed to bind to a
double stranded DNA comprising SEQ ID NO:1 and its
complement (SEQ ID NO:2).
In still another embodiment, the invention includes a com

pound of the formula:
55

or a pharmaceutically acceptable salt thereof, wherein
m is 10 or 11;
n is 9 or 10;
Im is desamino-imidazole;
60

65

each X is independently selected from 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-me
thylpyrrole (P) or B-alanine (B), subject to the proviso
that the compound contains no more than two I units;
y' is Y-aminobutyric acid (Y), (S)-2,4-diaminobutyric acid,
(R)-2,4-diaminobutyric acid (Y), (S)-2-(acety
lamino)-4-aminobutyric acid, or (R)-2-(acetylamino)-4aminobutyric acid (Yv);

US 8,993,609 B2
5
Yis B-alanine (B) or 4-amino-2-carbonyl-N-methylpyrrole
(P); and
A is 3,3'-diamino-N-methyldipropylamine (Ta) or dim
ethylaminopropylamine (Dp).
The sequence—CX) may, for example, be selected from
the group consisting of -PPBPPIBPP-, -PPBPIPBPPI-,
and -PPPBPPPBPP-. The sequence —(X), Y may, for
example, be free of Iunits and may be selected from the group
consisting of -PPBPPPBPPPB-,-BPBPPPBPPPB-, -PPPBPP
PBPPPB-, and -PPBPPPBPPPP-.
Also provided by the present invention is a method of
treating HPV infected cells comprising contacting the cells
with an effective amount of a compound in accordance with
the above-mentioned formula Im-CX),-y-CX), Y-A. A
method of treating HPV in a subject is also provided com
prising administering to the Subject an effective amount of a
compound in accordance with this formula. The compound
may, for example, be administered in the form of a pharma
ceutical composition comprising the compound and a phar
maceutically acceptable carrier.

10

15

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 compares the effect of cidofovir and IFNY with a
polyamide on HPV 16 copy number.
FIG. 2A shows a representative graph of the results of
Q-PCR to determine the ICs of polyamides. FIG. 2B shows
the dose-dependent decrease in HPV 16 DNA copy number in
cells treated with polyamides and the effect of polyamides on
cell viability.
FIG.3 shows a graph showing the dose-dependent effect of
polyamides on HPV 16 episomes.
FIG. 4 shows a Southern blot of HPV DNA clearance by
polyamides.
FIG. 5 compares the efficacy of varying concentrations of
the polyamide 1037 to those of distamycin A and cidofovir on
HPV 16 copy number and the corresponding effect of each on
cell viability.
FIG. 6 shows the chemical structure of an exemplary
polyamide.
FIG. 7 shows the effect of withdrawing a polyamide from
keratinocytes on HPV 16 episomes.
FIG. 8 is a diagram of different polyamide binding motifs
which is adapted from P. B. Dervan and B. S. Edelson, Rec
ognition of the DNA minor groove by pyrroleimidazole
polyamides, Curr Opin Struct Biol 13 (2003)284-99.

25
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stituted with one or more Substituents such as halo;

40

45

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

50

As used herein, the following definitions shall apply unless
otherwise indicated. For purposes of this invention, the
chemical elements are identified in accordance with the Peri

odic Table of the Elements, CAS version, Handbook of

Chemistry and Physics, 75th Ed. Additionally, general prin
ciples of organic chemistry are described in "Organic Chem
istry'. Thomas Sorrell, University Science Books, Sausalito:
1999, and “March's Advanced Organic Chemistry, 5th Ed.,
Ed. Smith, M. B. and March, J., John Wiley & Sons, New

55

60

York: 2001.

As used herein the term “aliphatic' encompasses the terms
alkyl, alkenyl, alkynyl, each of which being optionally Sub
stituted as set forth below.

As used herein, an “alkyl group refers to a saturated ali
phatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4)
carbon atoms. An alkyl group can be straight or branched.

6
Examples of alkyl groups include, but are not limited to,
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, n-heptyl or 2-ethylhexyl. An alkyl group
can be substituted (i.e., optionally substituted) with one or
more Substituents such as halo; cycloaliphatic e.g.,
cycloalkyl or cycloalkenyl; heterocycloaliphatic e.g., het
erocycloalkyl or heterocycloalkenyl: aryl; heteroaryl;
alkoxy; aroyl; heteroaroyl; acyl e.g., (aliphatic)carbonyl,
(cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl:
nitro; cyano; amido e.g., (cycloalkylalkyl)carbonylamino,
arylcarbonylamino, aralkylcarbonylamino, (heterocy
cloalkyl)carbonylamino, (heterocycloalkylalkyl)carbony
lamino, heteroarylcarbonylamino, heteroaralkylcarbony
lamino alkylaminocarbonyl, cycloalkylaminocarbonyl,
heterocycloalkylaminocarbonyl, arylaminocarbonyl, or het
eroarylaminocarbonyl, amino e.g., aliphaticamino,
cycloaliphaticamino, or heterocycloaliphaticamino; Sulfo
nyl e.g., aliphatic-S(O) ; Sulfinyl; Sulfanyl; Sulfoxy; urea;
thiourea; Sulfamoyl; Sulfamide; oxo; carboxy; carbamoyl;
cycloaliphaticoxy; heterocycloaliphaticoxy: aryloxy; het
eroaryloxy; aralkyloxy; heteroarylalkoxy; alkoxycarbonyl:
alkylcarbonyloxy; or hydroxy. Without limitation, some
examples of substituted alkyls include carboxyalkyl (such as
HOOC-alkyl, alkoxycarbonylalkyl, and alkylcarbonyloxy
alkyl); cyanoalkyl, hydroxyalkyl; alkoxyalkyl, acylalkyl;
aralkyl, (alkoxyarypalkyl: (Sulfonylamino)alkyl (such as
alkyl-S(O)-aminoalkyl); aminoalkyl, amidoalkyl; (cy
cloaliphatic)alkyl; or haloalkyl.
As used herein, a halo-aliphatic group refers to an aliphatic
group that is substituted with 1-3 halo atoms, wherein ali
phatic and halo are defined herein. Substitution can occur at
any chemically feasible carbon atom.
As used herein, an “alkenyl group refers to an aliphatic
carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbonatoms
and at least one double bond. Like an alkyl group, an alkenyl
group can be straight or branched. Examples of an alkenyl
group include, but are not limited to, allyl, isoprenyl, 2-bute
nyl and 2-hexenyl. An alkenyl group can be optionally Sub

65

cycloaliphatic e.g., cycloalkyl or cycloalkenyl; heterocy
cloaliphatic e.g., heterocycloalkyl or heterocycloalkenyl:
aryl; heteroaryl; alkoxy; aroyl; heteroaroyl; acyl e.g., (ali
phatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocy
cloaliphatic)carbonyl; nitro; cyano; amido e.g., (cycloalky
lalkyl)carbonylamino,
arylcarbonylamino,
aralkylcarbonylamino, (heterocycloalkyl)carbonylamino,
(heterocycloalkylalkyl)carbonylamino, heteroarylcarbony
lamino, heteroaralkylcarbonylamino alkylaminocarbonyl,
cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl,
arylaminocarbonyl, or heteroarylaminocarbonyl; amino
e.g., aliphaticamino, cycloaliphaticamino, heterocy
cloaliphaticamino, oraliphaticsulfonylamino; Sulfonyl e.g.,
alkyl-S(O) , cycloaliphatic-S(O) , or aryl-S(O) ;
Sulfinyl; Sulfanyl; Sulfoxy; urea; thiourea; Sulfamoyl; Sulfa
mide; oxo; carboxy; carbamoyl, cycloaliphaticoxy; heterocy
cloaliphaticoxy: aryloxy; heteroaryloxy; aralkyloxy; het
eroaralkoxy; alkoxycarbonyl; alkylcarbonyloxy; or hydroxy.
Without limitation, some examples of substituted alkenyls
include cyanoalkenyl, alkoxyalkenyl, acylalkenyl, hydroxy
alkenyl, aralkenyl, (alkoxyaryl)alkenyl, (Sulfonylamino)alk
enyl (such as (alkyl-S(O)-aminoalkenyl), aminoalkenyl,
amidoalkenyl, (cycloaliphatic)alkenyl, or haloalkenyl.
As used herein, an “alkynyl group refers to an aliphatic
carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbonatoms
and has at least one triple bond. An alkynyl group can be
straight or branched. Examples of an alkynyl group include,
but are not limited to, propargyl and butynyl. An alkynyl
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group can be optionally substituted with one or more Sub
stituents such as aroyl; heteroaroyl; alkoxy, cycloalkyloxy;
heterocycloalkyloxy, aryloxy; heteroaryloxy; aralkyloxy;
nitro; carboxy; cyano; halo: hydroxy, Sulfo, mercapto: Sulfa
nyl e.g., aliphatic-S - or cycloaliphatic-S-; Sulfinyl e.g.,
aliphatic-S(O)— or cycloaliphatic-S(O)—; Sulfonyl e.g.,
aliphatic-S(O)

,

aliphaticamino-S(O)

,

O

cycloaliphatic-S(O) ; amido e.g., aminocarbonyl, alky
laminocarbonyl, alkylcarbonylamino, cycloalkylaminocar
bonyl, heterocycloalkylaminocarbonyl, cycloalkylcarbony
lamino,
arylaminocarbonyl,
arylcarbonylamino,
aralkylcarbonylamino, (heterocycloalkyl)carbonylamino,
(cycloalkylalkyl)carbonylamino,
heteroaralkylcarbony
lamino, heteroarylcarbonylamino or heteroarylaminocarbo
nyl; urea; thiourea; Sulfamoyl; Sulfamide; alkoxycarbonyl:
alkylcarbonyloxy, cycloaliphatic; heterocycloaliphatic; aryl;
heteroaryl; acyl e.g., (cycloaliphatic)carbonyl or (heterocy
cloaliphatic)carbonyl; amino e.g., aliphaticamino; Sul
foXy; oxo; carbamoyl; (cycloaliphatic)oxy; (heterocy
cloaliphatic)oxy; or (heteroaryl)alkoxy.
As used herein, an "amido' encompasses both 'aminocar
bonyl and “carbonylamino”. These terms when used alone
or in connection with another group refers to an amido group

such as N(R)-C(O) R' or - C(O) N(R), when
used terminally, and —C(O) N(R)- or N(R)- C
(O)— when used internally, wherein R and R are defined

below. Examples of amido groups include alkylamido (Such
as alkylcarbonylamino or alkylaminocarbonyl), (heterocy
cloaliphatic)amido, (heteroaralkyl)amido, (heteroaryl)
amido, (heterocycloalkyl)alkylamido, arylamido, aralkyla
mido, (cycloalkyl)alkylamido or cycloalkylamido.

10
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As used herein, an "amino” group refers to NR'R''

wherein each of R and R is independently hydrogen, alkyl,

cycloaliphatic, (cycloaliphatic)aliphatic, aryl, araliphatic,
heterocycloaliphatic, (heterocycloaliphatic)aliphatic, het
eroaryl, carboxy, Sulfanyl, Sulfinyl, Sulfonyl, (aliphatic)car
bonyl, (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)
carbonyl,
arylcarbonyl,
(araliphatic)carbonyl,
(heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)ali
phatic)carbonyl, (heteroaryl)carbonyl, or (heteroaraliphatic)
carbonyl, each of which being defined herein and being
optionally Substituted. Examples of amino groups include
alkylamino, dialkylamino or arylamino. When the term
“amino' is not the terminal group (e.g., alkylcarbonylamino),

it is represented by NR -. R has the same meaning as

35
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defined above.

As used herein, an “aryl group used alone or as part of a
larger moiety as in “aralkyl”, “aralkoxy’, or “aryloxyalkyl
refers to monocyclic (e.g., phenyl); bicyclic (e.g., indenyl,
naphthalenyl, tetrahydronaphthyl, tetrahydroindenyl); and
tricyclic (e.g., fluorenyl tetrahydrofluorenyl, or tetrahydroan
thracenyl, anthracenyl) ring systems in which the monocyclic
ring system is aromatic or at least one of the rings in a bicyclic
or tricyclic ring system is aromatic. The bicyclic and tricyclic
groups include benzofused 2-3 membered carbocyclic rings.
For example, a benzofused group includes phenyl fused with
two or more Cas carbocyclic moieties. An aryl is optionally
Substituted with one or more substituents including aliphatic
e.g., alkyl, alkenyl, or alkynyl; cycloaliphatic; (cy
cloaliphatic)aliphatic; heterocycloaliphatic; (heterocy
cloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cy
cloaliphatic)oxy; (heterocycloaliphatic)oxy, aryloxy;
heteroaryloxy: (araliphatic)oxy; (heteroaraliphatic)oxy;
aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocy
clic ring of a benzofused bicyclic or tricyclic aryl), nitro:
carboxy; amido; acyl e.g., aliphaticcarbonyl, (cycloaliphat
ic)carbonyl,
((cycloaliphatic)aliphatic)carbonyl,
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(araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((het
erocycloaliphatic)aliphatic)carbonyl, or (heteroaraliphatic)
carbonyl; Sulfonyl e.g., aliphatic-S(O) - or amino
S(O) : Sulfinyl e.g., aliphatic-S(O)— or cycloaliphatic-S
(O)—; Sulfanyl e.g., aliphatic-S : cyano; halo: hydroxy:
mercapto; Sulfoxy, urea; thiourea; Sulfamoyl; Sulfamide; or
carbamoyl. Alternatively, an aryl can be unsubstituted.
Non-limiting examples of substituted aryls include
haloaryl e.g., mono-, di (such as p.m-dihaloaryl), and (triha
lo)aryl; (carboxy)aryl e.g., (alkoxycarbonyl)aryl, (aralkyl)
carbonyloxy)aryl, and (alkoxycarbonyl)aryl: (amido)aryl
e.g., (aminocarbonyl)aryl, (((allylamino)alkyl)aminocarbo
nyl)aryl, (alkylcarbonyl)aminoaryl, (arylaminocarbonyl)
aryl, and (((heteroaryl)amino)carbonyl)aryl; aminoaryl
e.g., ((alkylsulfonyl)amino)aryl or ((dialkyl)amino)aryl;
(cyanoalkyl)aryl; (alkoxy)aryl; (sulfamoyl)aryl e.g., (ami
nosulfonyl)aryl; (alkylsulfonyl)aryl; (cyano)aryl; (hydroxy
alkyl)aryl; ((alkoxy)alkyl)aryl; (hydroxy)aryl, ((carboxy)
alkyl)aryl; (((dialkyl)amino)alkyl)aryl; (nitroalkyl)aryl;
(((alkylsulfonyl)amino)alkyl)aryl; ((heterocycloaliphatic)
carbonyl)aryl; ((alkylsulfonyl)alkyl)aryl; (cyanoalkyl)aryl;
(hydroxyalkyl)aryl; (alkylcarbonyl)aryl; alkylaryl: (triha
loalkyl)aryl; p-amino-m-alkoxycarbonylaryl; p-amino-mcyanoaryl; p-halo-m-aminoaryl; or (m-(heterocy
cloaliphatic)-O-(alkyl))aryl.
As used herein, an “araliphatic' such as an “aralkyl group
refers to an aliphatic group (e.g., a C alkyl group) that is
substituted with an aryl group. “Aliphatic,” “alkyl and
“aryl' are defined herein. An example of an araliphatic such
as an aralkyl group is benzyl.
As used herein, an “aralkyl group refers to an alkyl group
(e.g., a Calkyl group) that is substituted with an aryl group.
Both “alkyland “aryl have been defined above. An example
of an aralkyl group is benzyl. An aralkyl is optionally Substi
tuted with one or more Substituents such as aliphatic e.g.,
alkyl, alkenyl, or alkynyl, including carboxyalkyl, hydroxy
alkyl, or haloalkyl such as trifluoromethyl: cycloaliphatic
e.g., cycloalkyl or cycloalkenyl; (cycloalkyl)alkyl; hetero
cycloalkyl; (heterocycloalkyl)alkyl, aryl; heteroaryl; alkoxy;
cycloalkyloxy; heterocycloalkyloxy, aryloxy; heteroaryloxy;
aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; nitro; car
boxy; alkoxycarbonyl; alkylcarbonyloxy; amido e.g., ami
nocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino,
(cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralky
lcarbonylamino, (heterocycloalkyl)carbonylamino, (hetero
cycloalkylalkyl)carbonylamino, heteroarylcarbonylamino,
or heteroaralkylcarbonylamino; cyano; halo: hydroxy; acyl:
mercapto; alkylsulfanyl; Sulfoxy; urea; thiourea; Sulfamoyl;
Sulfamide; oxo; or carbamoyl.
As used herein, a “bicyclic ring system” includes 8-12
(e.g., 9, 10 or 11) membered structures that form two rings,
wherein the two rings have at least one atom in common (e.g.,
2 atoms in common). Bicyclic ring systems include bicy
cloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicyclo
heteroaliphatics, bicyclic aryls and bicyclic heteroaryls.
As used herein, a “cycloaliphatic' group encompasses a
“cycloalkyl group and a “cycloalkenyl group, each of
which being optionally substituted as set forth below.
As used herein, a “cycloalkyl group refers to a saturated
carbocyclic mono- or bicyclic (fused or bridged) ring of 3-10
(e.g., 5-10) carbon atoms. Examples of cycloalkyl groups
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-inde
nyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2
octyl, bicyclo[3.3.1nonyl, bicyclo[3.3.2decyl, bicyclo
2.2.2]octyl, adamantyl, azacycloalkyl or (aminocarbonyl)
cycloalkyl)cycloalkyl. A “cycloalkenyl group, as used
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herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g.,
4-8) carbon atoms having one or more double bonds.
Examples of cycloalkenyl groups include cyclopentenyl, 1,4cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro
indenyl, octahydro-naphthyl, cyclohexenyl, cyclopentenyl,
bicyclo[2.2.2]octenyl, or bicyclo[3.3.1 nonenyl. A
cycloalkyl or cycloalkenyl group can be optionally Substi
tuted with one or more Substituents such as aliphatic e.g.,
alkyl, alkenyl, or alkynyl; cycloaliphatic; (cycloaliphatic)
aliphatic; heterocycloaliphatic; (heterocycloaliphatic) ali
phatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (hetero
cycloaliphatic)oxy: aryloxy; heteroaryloxy: (araliphatic)oxy;
(heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; amido
e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbony
lamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)car
bonylamino, (araliphatic)carbonylamino, (heterocy
cloaliphatic)carbonylamino,
((heterocycloaliphatic)
aliphatic)carbonylamino, (heteroaryl)carbonylamino, or
(heteroaraliphatic)carbonylamino; nitro; carboxy e.g.,
HOOC-, alkoxycarbonyl, or alkylcarbonyloxy; acyl e.g.,
(cycloaliphatic)carbonyl, ((cycloaliphatic) aliphatic)carbo
nyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl,
((heterocycloaliphatic)aliphatic)carbonyl,

O

10

15

(het

eroaraliphatic)carbonyl: cyano; halo: hydroxy, mercapto:
Sulfonyl e.g., alkyl-S(O) - and aryl-S(O) ; Sulfinyl
e.g., alkyl-S(O)—; Sulfanyl e.g., alkyl-S—; Sulfoxy; urea;
thiourea; Sulfamoyl; Sulfamide; oxo; or carbamoyl.
As used herein, "cyclic moiety' includes cycloaliphatic,
heterocycloaliphatic, aryl or heteroaryl, each of which has
been defined previously.
As used herein, the term "heterocycloaliphatic' encom
passes a heterocycloalkyl group and a heterocycloalkenyl
group, each of which being optionally substituted as set forth
below. As used herein, a "heterocycloalkyl group refers to a
3-10 membered mono- or bicyclic (fused or bridged) (e.g., 5
to 10-membered mono- or bicyclic) Saturated ring structure,
in which one or more of the ring atoms is a heteroatom (e.g.,
N, O, S, or combinations thereof). Examples of a heterocy
cloalkyl group include piperidyl, piperaZyl, tetrahydropyra
nyl, tetrahydrofuryl, 1,4-dioxolanyl, 1,4-dithianyl, 1.3-diox
olanyl.
oxazolidyl,
isoxazolidyl,
morpholinyl,
thiomorpholyl, octahydrobenzofuryl, octahydrochromenyl,
octahydrothiochromenyl, octahydroindolyl, octahydropy
rindinyl,
decahydroquinolinyl,
octahydrobenzob.
thiopheneyl, 2-oxa-bicyclo2.2.2]octyl, 1-aza-bicyclo2.2.2
octyl, 3-azabicyclo3.2.1]octyl, and 2,6-dioxa-tricyclo
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3.3.1.07nonyl. A monocyclic heterocycloalkyl group can

be fused with a phenyl moiety to form a heteroaryl such as
tetrahydroisoquinoline. A "heterocycloalkenyl group, as
used herein, refers to a mono- or bicyclic (e.g., 5- to 10-mem
bered mono- or bicyclic) non-aromatic ring structure having

50

oxy;

55

(heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a
non-aromatic carbocyclic or heterocyclic ring of a bicyclic or
tricyclic heteroaryl); carboxy; amido; acyl e.g., aliphaticcar
bonyl; (cycloaliphatic)carbonyl: ((cycloaliphatic)aliphatic)
carbonyl: (araliphatic)carbonyl; (heterocycloaliphatic)car

one or more double bonds, and wherein one or more of the

ring atoms is a heteroatom (e.g., N, O, or S). Monocyclic and
bicycloheteroaliphatics are numbered according to standard
chemical nomenclature.

A heterocycloalkyl or heterocycloalkenyl group can be
optionally Substituted with one or more substituents such as
aliphatic e.g., alkyl, alkenyl, or alkynyl; cycloaliphatic; (cy
cloaliphatic)aliphatic; heterocycloaliphatic; (heterocy
cloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cy
cloaliphatic)oxy; (heterocycloaliphatic)oxy, aryloxy;
heteroaryloxy: (araliphatic)oxy; (heteroaraliphatic)oxy;
aroyl; heteroaroyl; amino; amido e.g., (aliphatic)carbony
lamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)
carbonylamino,
(heterocycloaliphatic)carbonylamino,
((heterocycloaliphatic)aliphatic)carbonylamino, (heteroaryl)

10
carbonylamino, or (heteroaraliphatic)carbonylamino; nitro:
carboxy (e.g., HOOC-, alkoxycarbonyl, or alkylcarbony
loxy; acyl e.g., (cycloaliphatic)carbonyl, ((cycloaliphatic)
aliphatic)carbonyl, (araliphatic)carbonyl, (heterocy
cloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)car
bonyl, or (heteroaraliphatic)carbonyl; nitro; cyano; halo;
hydroxy, mercapto: Sulfonyl e.g., alkylsulfonyl or arylsulfo
nyl; Sulfinyl e.g., alkylsulfinyl; Sulfanyl e.g., alkylsulfa
nyl; Sulfoxy, urea; thiourea; Sulfamoyl; Sulfamide; oxo; or
carbamoyl.
A "heteroaryl group, as used herein, refers to a monocy
clic, bicyclic, or tricyclic ring system having 4 to 15 ring
atoms wherein one or more of the ring atoms is a heteroatom
(e.g., N, O, S, or combinations thereof) and in which the
monocyclic ring system is aromatic or at least one of the rings
in the bicyclic or tricyclic ring systems is aromatic. A het
eroaryl group includes a benzofused ring system having 2 to
3 rings. For example, a benzofused group includes benzo
fused with one or two 4- to 8-membered heterocycloaliphatic
moieties (e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl,
indolinyl, benzobfuryl, benzobthiophenyl, quinolinyl or
isoquinolinyl). Some examples of heteroaryl are aZetidinyl,
pyridyl, 1H-indazolyl, furyl, pyrrolyl, thienyl, thiazolyl,
oxazolyl, imidazolyl, tetrazolyl, benzofuryl, isoquinolinyl,
benzthiazolyl, Xanthene, thioxanthene, phenothiazine, dihy
droindole, benzo. 1.3dioxole, benzobfuryl, benzob.
thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, puryl,
cinnolyl, quinolyl, quinazolyl, cinnolyl, phthalazyl, quinox
alyl, isoquinolyl, 4H-quinolizyl, benzo-1,2,5-thiadiazolyl, or
1.8-naphthyridyl.
Without limitation, monocyclic heteroaryls include furyl,
thiophenyl, 2H-pyrrolyl pyrrolyl, oxazolyl, thiazolyl, imida
Zolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1.3,4-thiadiazolyl,
2H-pyranyl, 4-H-pyranyl, pyridyl, pyridaZyl, pyrimidyl,
pyrazolyl pyrazyl, or 1.3.5-triaZyl. Monocyclic heteroaryls
are numbered according to standard chemical nomenclature.
Without limitation, bicyclic heteroaryls include indolizyl,
indolyl, isoindolyl, 3H-indolyl, indolinyl, benzobfuryl,
benzobthiophenyl, quinolinyl, isoquinolinyl, indolizyl.
isoindolyl, indolyl, benzobfuryl, bexobthiophenyl, inda
Zolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl.
quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, qui
noxalyl, 1.8-naphthyridyl, or pteridyl. Bicyclic heteroaryls
are numbered according to standard chemical nomenclature.
A heteroaryl is optionally substituted with one or more
Substituents such as aliphatic e.g., alkyl, alkenyl, or alkynyl:
cycloaliphatic;
(cycloaliphatic)aliphatic;
heterocy
cloaliphatic; (heterocycloaliphatic)aliphatic; aryl; het
eroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)

bonyl:

60

aryloxy;

heteroaryloxy;

(araliphatic)oxy;

((heterocycloaliphatic)aliphatic)carbonyl:

O

(heteroaraliphatic)carbonyl: Sulfonyl e.g., aliphatic
S(O) - or amino-S(O) ; Sulfinyl e.g., aliphatic-S
(O)—; Sulfanyl e.g., aliphatic-S-: nitro; cyano; halo;
hydroxy, mercapto: Sulfoxy, urea; thiourea; Sulfamoyl; Sul
famide; or carbamoyl. Alternatively, a heteroaryl can be
unsubstituted.
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Non-limiting examples of substituted heteroaryls include
(halo)heteroaryl e.g., mono- and di-(halo)heteroaryl; (car
boxy)heteroaryl e.g., (alkoxycarbonyl)heteroaryl; cyano
heteroaryl; aminoheteroaryle.g., ((alkylsulfonyl)amino)het
eroaryl and (dialkyl)amino)heteroaryl: (amido)heteroaryl
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e.g., aminocarbonylheteroaryl, (alkylcarbonyl)amino)het
eroaryl, ((((alkyl)amino)alkyl)aminocarbonyl)heteroaryl,
(((heteroaryl)amino)carbonyl)heteroaryl,
((heterocy
cloaliphatic)carbonyl)heteroaryl, and (alkylcarbonyl)
amino)heteroaryl; (cyanoalkyl)heteroaryl; (alkoxy)het
eroaryl; (sulfamoyl)heteroaryl e.g., (aminosulfonyl)
heteroaryl: (Sulfonyl)heteroaryl e.g., (alkylsulfonyl)
heteroaryl; (hydroxyalkyl)heteroaryl; (alkoxyalkyl)
heteroaryl; (hydroxy)heteroaryl; ((carboxy)alkyl)heteroaryl;
((dialkyl)amino)alkylheteroaryl; (heterocycloaliphatic)
heteroaryl; (cycloaliphatic)heteroaryl; (nitroalkyl)het
eroaryl; (((alkylsulfonyl)amino)alkyl)heteroaryl; ((alkylsul
fonyl)alkyl)heteroaryl; (cyanoalkyl)heteroaryl: (acyl)
heteroaryl e.g., (alkylcarbonyl)heteroaryl; (alkyl)
heteroaryl,

and

(haloalkyl)heteroaryl

e.g.,

trihaloalkylheteroaryl.
A "heteroaraliphatic' (such as a heteroaralkyl group) as
used herein, refers to an aliphatic group (e.g., a C alkyl
group) that is substituted with a heteroaryl group. “Aliphatic.”
“alkyl, and "heteroaryl have been defined above.
A "heteroaralkyl group, as used herein, refers to an alkyl
group (e.g., a C alkyl group) that is substituted with a
heteroaryl group. Both “alkyl and "heteroaryl have been
defined above. A heteroaralkyl is optionally substituted with
one or more Substituents such as alkyl (e.g., carboxyalkyl,
hydroxyalkyl, and haloalkyl such as trifluoromethyl); alk
enyl; alkynyl, cycloalkyl; (cycloalkyl)alkyl; heterocy
cloalkyl; (heterocycloalkyl)alkyl: aryl; heteroaryl; alkoxy:
cycloalkyloxy; heterocycloalkyloxy, aryloxy; heteroaryloxy;
aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; nitro; car
boxy; alkoxycarbonyl: alkylcarbonyloxy; aminocarbonyl:
alkylcarbonylamino; cycloalkylcarbonylamino; (cycloalky
lalkyl)carbonylamino: arylcarbonylamino: aralkylcarbony
lamino; (heterocycloalkyl)carbonylamino; (heterocycloalky
lalkyl)carbonylamino;
heteroarylcarbonylamino;
heteroaralkylcarbonylamino; cyano; halo; hydroxy; acyl:
mercapto; alkylsulfanyl; Sulfoxy; urea; thiourea; Sulfamoyl;
Sulfamide; oxo; or carbamoyl.
As used herein, an “acyl group refers to a formyl group or

12

- NR S(O), NR' when used internally, wherein R,
Rand R? have been defined above.

As used herein, a “sulfamoyl group refers to the structure

—S(O), NR'R' or NR S(O). R^ when used termi
nally; or —S(O). NR or NR S(O) when used
internally, wherein R, R and R? are defined above.
As used herein a “sulfanyl group refers to S R when
used terminally and - S - when used internally, wherein R'
10

As used herein a “sulfinyl" group refers to S(O) R'
wherein R has been defined above. Exemplary sulfinyl

when used terminally and —S(O)— when used internally,
15

As used herein, a "sulfonyl group refers to S(O) R'
wherein R has been defined above. Exemplary sulfonyl
groups include aliphatic-S(O) , aryl-S(O) , (cy
cloaliphatic(aliphatic))-S(O) , cycloaliphatic-S(O) ,
heterocycloaliphatic-S(O) , heteroaryl-S(O) , (cy
cloaliphatic(amido(aliphatic)))-S(O) or the like.

25

As used herein, a “halogen' or “halo' group refers to
fluorine, chlorine, bromine or iodine.
30

35

As used herein, an “oxo’ refers to —O.

(R)-N-alkyl-.
40
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As used herein, a “cyanoalkyl refers to the structure (NC)alkyl-.
As used herein, a “urea group refers to the structure

- NR CO NR'R' and a “thiourea” group refers to the
structure —NR CS NR'R' when used terminally and
NR CONR
or NR CS NR' when used
internally, wherein R, R and R? have been defined above.
As used herein, a "guanidine' group refers to the structure
N=C(N(RR))N(RR) wherein R and e have been
defined above.

As used herein, the term "amidino' group refers to the

50

structure -C=(NR)N(RR) wherein Rande have been

defined above.

In general, the term “vicinal refers to the placement of
Substituents on a group that includes two or more carbon
atoms, wherein the Substituents are attached to adjacent car
55

bon atoms.

In general, the term “geminal refers to the placement of
Substituents on a group that includes two or more carbon

—COOR, OC(O)H, OC(O)R when used as a terminal

- NR S(O), NR'R' when used terminally and

As used herein, an “alkoxycarbonyl, which is encom
passed by the term carboxy, used alone or in connection with
another group refers to a group such as alkyl-O C(O)—.
As used herein, an “alkoxyalkyl refers to an alkyl group
such as alkyl-O-alkyl-, wherein alkyl has been defined above.
As used herein, a “carbonyl refers to —C(O)—.
As used herein, an "aminoalkyl refers to the structure

O-R wherein R and Rhave been defined above and R^

group; or —OC(O)— or —C(O)O— when used as an inter
nal group.
As used herein, a "haloaliphatic group refers to an ali
phatic group Substituted with 1-3 halogen. For instance, the
term haloalkyl includes the group —CF.
As used herein, a “mercapto' group refers to —SH.
As used herein, a “sulfo' group refers to —SOH or
—SOR when used terminally or S(O), when used
internally.
As used herein, a “sulfamide' group refers to the structure

As used herein, a "sulfoxy” group refers to —O SO. R.
or -SO-O-R, when used terminally and —O S(O)—
or S(O)—O— when used internally, where R has been
defined above.

having the structure - O CO. NR'R' or -NR CO
can be aliphatic, aryl, araliphatic, heterocycloaliphatic, het
eroaryl or heteroaraliphatic.
As used herein, a “carboxy” group refers to —COOH,

groups include aliphatic-S(O)—, aryl-S(O)—, (cy
cloaliphatic(aliphatic))-S(O) cycloalkyl-S(O)—, hetero
cycloaliphatic-S(O)—, heteroaryl-S(O)—, or the like.

when used terminally and —S(O) - when used internally,

R C(O)— (such as -alkyl-C(O)—, also referred to as
“alkylcarbonyl) where R and “alkyl have been defined

previously. Acetyl and pivaloyl are examples of acyl groups.
As used herein, an “aroyl or "heteroaroyl refers to an
aryl-C(O)— or a heteroarylC(O)—. The aryl and heteroaryl
portion of the aroyl or heteroaroyl is optionally substituted as
previously defined.
As used herein, an “alkoxy' group refers to an alkyl-Ogroup where “alkyl has been defined previously.
As used herein, a “carbamoyl group refers to a group

has been defined above. Examples of sulfanyls include ali
phatic-S cycloaliphatic-S , aryl-S—, or the like.

atoms, wherein the Substituents are attached to the same
carbon atom.
60

The terms “terminally' and “internally” refer to the loca
tion of a group within a Substituent. A group is terminal when
the group is present at the end of the substituent not further
bonded to the rest of the chemical structure. Carboxyalkyl,

65

terminally. A group is internal when the group is present in the

i.e., RO(O)C-alkyl is an example of a carboxy group used

middle of a substituent to at the end of the substituent bound

to the rest of the chemical structure. Alkylcarboxy (e.g., alkyl
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C(O)O— or alkyl-OC(O)—) and alkylcarboxyaryl (e.g.,
alkyl-C(O)O-aryl- or alkyl-O(CO)-aryl-) are examples of
carboxy groups used internally.
As used herein, the term "amidino' group refers to the

structure -C=(NR)N(RR) wherein RandR have been

5

defined above.

As used herein, "cyclic group' includes mono-, bi- and
tri-cyclic ring systems including cycloaliphatic, heterocy
cloaliphatic, aryl or heteroaryl, each of which has been pre
viously defined.
As used herein, a “bridged bicyclic ring system” refers to a
bicyclic heterocyclicalipahtic ring system or bicyclic
cycloaliphatic ring system in which the rings are bridged.
Examples of bridged bicyclic ring systems include, but are
not limited to, adamantanyl, norbornanyl, bicyclo3.2.1]oc
tyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1nonyl, bicyclo[3.2.3
nonyl, 2-oxa-bicyclo2.2.2]octyl, 1-aza-bicyclo2.2.2]octyl,
3-azabicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03.7
nonyl. A bridged bicyclic ring system can be optionally Sub
stituted with one or more Substituents such as alkyl (including
carboxyalkyl, hydroxyalkyl, and haloalkyl Such as trifluo
romethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl,
heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl,
alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, het
eroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl,
nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocar
bonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cy
cloalkylalkyl)carbonylamino, arylcarbonylamino, aralkyl
carbonylamino,
(heterocycloalkyl)carbonylamino,
(heterocycloalkylalkyl)carbonylamino, heteroarylcarbony
lamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy,
acyl, mercapto, alkylsulfanyl, Sulfoxy, urea, thiourea, Sulfa
moyl, Sulfamide, oxo, or carbamoyl.
As used herein, an “aliphatic chain” refers to a branched or
Straight aliphatic group (e.g., alkyl groups, alkenyl groups, or
alkynyl groups). A straight aliphatic chain has the structure
—CH2—, where V is 1-6. A branched aliphatic chain is a
straight aliphatic chain that is substituted with one or more
aliphatic groups. A branched aliphatic chain has the structure
—CHQ- where Q is hydrogen or an aliphatic group; how
ever, Q shall be analiphatic group in at least one instance. The
termaliphatic chain includes alkyl chains, alkenyl chains, and
alkynyl chains, where alkyl, alkenyl and alkynyl are defined
above.
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As used herein, an effective amount is defined as the
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The phrase “optionally substituted is used interchange
ably with the phrase “substituted or unsubstituted. As
described herein, compounds of the invention can optionally
be substituted with one or more substituents, such as are

illustrated generally above, or as exemplified by particular
classes, Subclasses, and species of the invention. As described
herein, the variables contained herein encompass specific
groups, such as alkyl and aryl. Unless otherwise noted, each
of the specific groups can be optionally Substituted with one

50

or more substituents described herein. Each substituent of a

55

specific group is further optionally substituted with one to
three of halo, cyano, oxoalkoxy, hydroxy, amino, nitro, aryl,
haloalkyl and alkyl. For instance, an alkyl group can be Sub
stituted with alkylsulfanyl and the alkylsulfanyl can, in turn,
be optionally substituted with one to three of halo, cyano,
oXoalkoxy, hydroxy, amino, nitro, aryl, haloalkyl and alkyl.
As an additional example, the cycloalkyl portion of a (cy
cloalkyl)carbonylamino can be optionally substituted with
one to three of halo, cyano, alkoxy, hydroxy, nitro, haloalkyl
and alkyl. When two alkoxy groups are bound to the same
atom or adjacentatoms, the two alkoxy groups can formaring
together with the atom(s) to which they are bound.

14
In general, the term “substituted, whether preceded by the
term “optionally” or not, refers to the replacement of hydro
gen radicals in a given structure with the radical of a specified
substituent. Specific substituents are described above in the
definitions and below in the description of compounds and
examples thereof. Unless otherwise indicated, an optionally
Substituted group can have a Substituent at each Substitutable
position of the group, and when more than one position in any
given structure can be substituted with more than one Sub
stituent selected from a specified group, the Substituent can be
either the same or different at every position. A ring substitu
ent, such as a heterocycloalkyl, can be bound to another ring,
Such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g.,
both rings share one common atom. As one of ordinary skill
in the art will recognize, combinations of Substituents envi
sioned by this invention are those combinations that result in
the formation of stable or chemically feasible compounds.
The phrase “stable or chemically feasible.” as used herein,
refers to compounds that are not substantially altered when
subjected to conditions to allow for their production, detec
tion, and preferably their recovery, purification, and use for
one or more of the purposes disclosed herein. In some
embodiments, a stable compound or chemically feasible
compound is one that is not substantially altered when kept at
a temperature of 40°C. or less, in the absence of moisture or
other chemically reactive conditions, for at least a week. The
compounds of this invention may function in protonated (cat
ionic) forms and may cross membranes in neutral forms.
amount required to confer a therapeutic effect on the treated
patient, and is typically determined based on age, Surface
area, weight and condition of the patient. The interrelation
ship of dosages for animals and humans (based on milligrams
per meter squared of body surface) is described by Freireich
et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface
area may be approximately determined from height and
weight of the patient. See, e.g., Scientific Tables, Geigy Phar
maceuticals, Ardsley, N.Y., 537 (1970). As used herein,
"patient” refers to a mammal, including a human.
Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereo
meric, and geometric (or conformational)) forms of the struc
ture; for example, the R and S configurations for each asym
metric center, (Z) and (E) double bond isomers, and (Z) and
(E) conformational isomers. Therefore, single stereochemi
cal isomers as well as enantiomeric, diastereomeric, and geo
metric (or conformational) mixtures of the present com
pounds are within the scope of the invention. Unless
otherwise stated, all tautomeric forms of the compounds of
the invention are within the scope of the invention. Addition
ally, unless otherwise stated, structures depicted herein are
also meant to include compounds that differ only in the pres
ence of one or more isotopically enriched atoms. For
example, compounds having the present structures except for
the replacement of hydrogen by deuterium or tritium, or the

replacement of a carbon by a C- or C-enriched carbon are

within the scope of this invention. Such compounds are use
ful, for example, as analytical tools or probes in biological
assayS.
60

II. Chemical Background
Certain polyamide oligomers of nitrogen heterocycle
amino acids can be used to bind to particular regions of
65

double stranded DNA. The amino acids are often referred to

by the name of the parent heterocycle (e.g., pyrrole instead of
N-methyl-carboxy-4-aminopyrrole). Particularly, as com
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monly described in the literature, N-methyl imidazole
(Im. -Im-, -I- or I), des-amino-N-methyl imidazole (des-Im.
dIm. Im- or dI), and N-methylpyrrole (Py, -Py-, -P- or P) have
a specific affinity for particular bases. These groups are
shown along with other building blocks in structures I-VIII,
which represent the groups as they appear when incorporated
into a polyamide (as amides, etc.). The DNA specificity can
be modified based upon the order in which these compounds
are linked. It has been shown that there is specificity in that
G/C is complemented by Im/P (also denoted I/P), C/G is
complemented by Py/Im (also denoted P/I), and A/T and T/A
are redundantly complemented by Py/Py (also denoted P/P).
In effect, N-methyl imidazole and des-amino-N-methyl
imidazole tend to be associated with guanine, while N-meth
ylpyrrole is associated with cytosine, adenine and thymine.
By providing for two chains of the heterocycles, as 1 or 2
molecules, a 2:1 complex with double stranded DNA is
formed, with the two chains; of the oligomer antiparallel,
where G/C pairs have Im/Py injuxtaposition, C/G pairs have
Py/Im, and T/A pairs have Py/Py in juxtaposition. The het
erocycle oligomers are joined by amide (carbamyl)groups as
shown in I-VIII, where the NH may participate in hydrogen
bonding with nitrogen unpaired electrons, particularly of
adenine. Another building block, B-alanine (Structure III) can
take the place of some Pygroups.
Polyamides may be synthesized to form hairpin com
pounds by incorporating compounds, such as gamma-ami
nobutyric acid (Y) or gamma-amino-beta-aminobutyric acid
(Y), to allow a single polyamide to form a complex with
DNA. Such a structure has been found to significantly
increase the binding affinity of the polyamide to a target
sequence of DNA.
Beta-alanine (B) may be substituted for a pair of N-meth
ylpyrrole groups when an AT or TA base pair is the target
sequence. The added flexibility of the beta-alanine can help
the entire polyamide stay “in register with the target
sequence of DNA.
In some embodiments, the polyamide molecule begins
with des-amino-N-methyl imidazole (also referred to herein
as desamino-imidazole, des-Ilm, dIm, Im- or dI) which has a
specific affinity for guanosine. In other embodiments, the
polyamide molecule ends with incorporation of either
3-(Dimethylamino)propylamine (Da) or 3,3'-Diamino-Nmethyldipropylamine (Ta). Dye molecules can be incorpo
rated at the amino groups of the y-amino-butyric acid, the Ta,
or at both of these sites if both are available in the same
molecule.

More recently it has been discovered that the inclusion of a
new aromatic amino acid, 3-hydroxy-N-methylpyrrole (Hp),
when incorporated into a polyamide and paired opposite Py,
provides the means to discriminate A-T from T.A. White S.,
et al., Nature 391, 436-38 (1998). Unexpectedly, the replace
ment of a single hydrogenatom on the pyrrole with a hydroxy
group in an Hp/P pair regulates the affinity and the specificity
of a polyamide by an order of magnitude. Using Hp together
with P and Im or I in polyamides to form six aromatic amino
acid pairs (I/P Im/PP/Im, P/I, Hp/P and P/Hip) provides a
code to distinguish all four WatsonCrick base pairs in the
minor groove of DNA in environments in which Hp does not
decompose.
Naturally occurring pyrrole-containing polyamides such
as distamycin and netropsin, as well as their pyrrolefimida

16
Zole-containing synthetic analogs, bind with high affinity to
the minor groove of DNA. Direct evidence of specific polya
mide-DNA binding has been extensively reported by the Der
van group using X-ray crystallography, NMR structure deter
minations and quantitative affinity cleavage methods (Baird
and Dervan, 1998; Pilch et al., Biochemistry, 38, 2143-51,
1999; Pilch et al., Proc. Natl. Acad. Sci. USA, 93, 8306-11
10

1996; Wang, Ellervik, and Dervan, Bioorg. Med. Chem., 9,
653-7, 2001; White, Baird, and Dervan, Biochemistry, 35,
12532-27, 1996; White, Baird, and Dervan, Chem. Biol. 4,
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569-78, 1997, all of which are incorporated herein by refer
ence). Because of the H-bonding scheme, synthetic polya
mides can be designed to recognize specific DNA sequences.
The rules for DNA recognition by polyamides are summa
rized in the following paragraphs (White, Baird, and Dervan,
Chem. Biol. 4,569-78, 1997). The amidoN-Hofthe N-me
thylpyrrole (typically abbreviated Py, -Py-, -P- or P. structure
I) amino acid, as incorporated into a polyamide, binds to the
three nucleotides that present hydrogen bond acceptors in the
minor groove, or A. T and C (Kielkopfet al., Science, 282,
111-5, 1998; Kielkopf, et al., Nat. Struct. Biol. 5, 104-9,
1998; Melander, Herman, and Dervan, Chemistry, 6, 4487
97, 2000, all of which are incorporated herein by reference).
These nucleotides present only hydrogen bond acceptors to
the minor groove: A and C each offer one lone pair of elec
trons while T offers two lone pairs from the carbonyl oxygen
bound to C2. It is the amide NH of the hairpin pyrrole amino
acids that is the hydrogenbond donor. So, the pyrrole ring acts
as a curved spacer that presents amide NHS at the correct
distance and curvature to match up with the pattern of hydro
gen bond acceptors presented by A.C and T when located in
B-form DNA. Imidazole (Structure II below) is typically
abbreviated Im, -m-, -I- or I.
Structure I
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(denoted Pyor P)

Structure II
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(Im or I)
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Additional polyamide building blocks and binding rules
can be foundin (Urbachet al., J. Mol. Biol.,320,55-71, 2002:
Wang, Ellervik, and Dervan, Bioorg. Med. Chem., 9, 653-57,
2001, both of which are incorporated herein by reference).
However, these studies showed that (B-alanine (Structure III
(Bor-B-), below) can act as an FI-bond donor that is selective
for AT and C.
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-continued
(III)

VI

vis-A
(B)

For additional recognition, the y-aminobutyric acid (Struc
ture IV (Y or -y-) below) building block used to form the
hairpin turn (See FIG. 5) was reported by Dervan as recently
as 2009 (Farkas, Li, Dose, and Dervan, Bioorg. Med. Chem.
Lett. 19 (2009) 3919-3923, which is incorporated herein by
reference) to bind A/T and, in some cases G/C, base pairs. A
preference for A/T over G/C base pairs is shown for the
positively-charged amino tail that is present in most polya
mides. This mimics the cationic guanidine group in distamy
cin. (Parks, Baird, and Dervan, 1996: Pilch et al., Proc. Natl.
Acad. Sci. USA, 93, 8306-11, 1996; Trauger et al., Chem.
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v---(Ta)
*(des-Ilm, dI, dIm, Im- or I
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T.
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(Y)

Other building blocks include, without limitation, desa
mino-imidazole (Formula V (des-Ilm, dI, dIm, Im- or I-); as

40

used herein, the term “desamino-imidazole' means desa

mino-2-carbonyl-N-methylimidazole), (R)-2,4-diaminobu
tyric acid (Formula VI, Y) as well as the (S) isomer of
2,4-diaminobutyric acid, (R)-2-(acetylamino)-4-aminobu
tyric acid (Y) as well as the (S) isomer of 2-(acety
lamino)-4-aminobutyric acid, 3-(dimethylamino)-propy
lamine (Formula VII, Dp) and 3,3'-diamino-Nmethyldipropylamine (formula VIII, Ta). As with I-IV,
Structures V-VIII show the building blocks as incorporated
into a polyamide, e.g., VIII is shown as an amido diamine
whereas the parent Ta structure is a triamine. Structure VI
shows (R)-2,4-diaminobutyric acid incorporated into a polya
mide by reaction of the 4-amino group, thereby providing a
gamma turn in the molecule. Alternatively, (R)-2,4-diami
nobutyric acid may be incorporated into a polyamide by
reaction of the 2-amino group to provide an alpha turn. Simi
larly, the (S) isomer of 2,4-diaminobutyric acid may be incor
porated into the polyamide by reaction of eitheramino group.

(Dp)
VIII

Biol. 3,369-77, 1996: Urbach and Dervan, Proc. Natl. Acad.
Sci. USA, 98,4343-48, 2001; Urbachet al., J. Mol. Biol. 320,

55-71, 2002: Wang, Ellervik, and Dervan, Bioorg. Med.
Chem., 9, 653-57, 2001, each of which is incorporated herein
by reference). Standard hairpin polyamides show the highest
affinity for sequences that begin 5'-WWG-3', where W=A or

VII
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Polyamide-DNA binding has been reported to interfere
with protein-DNA binding (Fechter and Dervan, J. Am.
Chem. Soc., 125, 8476-85, 2003; Nguyen-Hackley et al.,
Biochemistry, 43, 6880-90, 2004; Schaal et al., Nucl. Acids
Res., 31, 1282–91, 2003, all of which are incorporated herein
by reference), and polyamides have been reported to inhibit
gene expression, presumably through competition with tran
scription factors for DNA binding sites (Dickinson et al.,
Biochemistry, 38, 10801-7, 1999: Supekova et al., Chem.
Biol. 9, 821-7, 2002; Weisz, 1997, all of which are incorpo
rated herein by reference). The expression of eukaryotic
genes is dependent on the formation of an active transcription
complex whose components are highly variable and pro
moter/gene dependent. Of primary importance in the assem
bly of a transcription complex is the binding of transcription
factors to their associated consensus sequences. While many
genes share transcription factors (TFS), the combination of a
specific TF binding site with the adjacent DNA unique to a
target gene may provide a relatively unique site within the
human genome. Thus, by designing polyamides to recognize
a TF binding site and some adjacent DNA, it has been pos
sible to target the promoter region of a unique gene even if the
TF has binding sites in the control regions of many genes.
III. HPV Targets

The present invention provides polyamides and analogs of
polyamide polymers that are useful for treating HPV infec
tions and other diseases. Without wishing to be bound by any
particular theory, the anti-HPV activity of polyamides pro
vides information for predicting and developing general rules
for designing polyamides against all HPV Subtypes, and to
other double-stranded DNA viruses. The methodology is use
ful in predicting which polyamide structures will possess
broad-spectrum anti-viral activity against other double
stranded DNA viruses, including Epstein-Barr viruses, her
pes viruses and pox viruses.
Time-course experiments of the anti-HPV action of the
polyamides of this invention led to the discovery that certain
active molecules decrease HPV DNA levels in human kera

tinocytes by >90% in as short as 30 min after drug treatment.
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11, 16 and 18, display the ability to displace or eliminate HPV

HPV DNA anchors itself to human chromosomes. The

various reasons for this include a need for close proximity to
human DNA replication elements for viral replication and
nuclear maintenance of episomes and proper segregation of
viral episomes into daughter cells during cell division. In
addition, while the processes are poorly understood, viral
genomes must evade innate immune systems that recognize
and eliminate foreign, or non-self, DNA.
Without being bound by theory, it is possible that polya
mides of the present invention are capable of either displacing
the circular HPV genome from the host chromosomes result
ing in their rapid loss and degradation of the episome, or that
the binding of polyamides to viral or nuclear DNA activates a
process resulting in specific elimination of viral rather than
host DNA sequences. One possible mechanism for loss of
viral DNA may include displacement of the episome from
cellular chromosomes leading first to export of the HPV DNA
from the host nucleus and second to rapid enzymatic degra
dation of the HPV DNA by nuclease enzymes. An additional
conclusion is that a major reason for tethering of HPV DNA
to host chromosomes is to protect the viral DNA from this
degradative pathway. Alternatively, the polyamides may alter
the physical properties of episomal DNA in the nucleus
resulting in recognition and elimination of the foreign DNA
by host defense mechanisms. These predictions can be
extended to other drugs that bind to the DNA minor groove,
and they can also be extended to other double-stranded DNA
viruses, including Epstein Barr viruses, that employ similar
or related Strategies for episomal maintenance.
In the case of HPV, it is known that tethering to the chro
mosomes occurs though long sequences of DNA bases A and
T. These AT tracts are targets for pyrrole-containing polya
mides, because of recognition of AT base pairs by pyrrole as
found in the natural product Distamycin, which can be con
sidered a partial progenitor of polyamide structure used for
DNA binding. Distamycin binds to AT-rich DNA, but it is a
Small enough molecule that very long AT tracts are not nec
essary to attract Distamycin: AT-regions only five bases long
are sufficient for recognition by Distamycin.
AT-rich regions of DNA in so-called “fragile DNA are
apparent targets of Distamycin, and are eliminated from cells
in response to Distamycin treatment. Furthermore, in model
systems of DNA rearrangement and processing, such as
found in ciliates and other microorganisms, it is AT-rich
regions that are targeted for elimination during genomic rear
rangements, suggesting that cells may retain an evolution
arily conserved mechanism for processing and elimination of
DNA, and that the AT-rich sequences involved are likely
targets for binding by pyrroles of naturally occurring or syn
thetic polyamides.
From the inventions described here, one can develop useful
drugs against DNA viruses such as the HPV subtypes by
considering the so-called selectivity index (SI: ratio of ICso to
TDs) and routine experimenting to determine an optimal
range of selectivity indices. Distamycin itself is too toxic for
most or all applications as an anti-viral, while our designed
and purpose-built long polyamides that target AT-rich DNA
regions have very low toxicity and very high SI in cell culture.
For example, Cidofovir gave an SI of 2.5, whereas NV 1028
gave an SI greater than 750. In some embodiments, the SI is

DNA from host chromosomes, which can result in broad
5

applicability against HPVs. These include HPV 11, which is
responsible, in part, for the frequently fatal disease known as
respiratory papillomatosis, as well as genital warts, HPV 1

10

genitalia, anus and cervix, respectively, and HPV 16 and 18,
which are responsible for cervical cancers.
The DNA sequences of HPV 16, HPV 18, HPV 11, HPV 6b
and HPV 1 genomes can be found at Genbank accession

and 6, which cause common warts and warts of the external

numbers NC 001526, NC 001357, M14119, NC 001355

and NC 001356, respectively.
IV. Polyamides
15

A. General Structure

The compounds of the invention comprise the active struc
tures in the family of compounds known as N-methylpyrrole
N-methylimidazole hairpin polyamide derivatives (Zhang,
W., T. Bando, and H. Sugiyama (2006) J. Am. Chem. Soc.
128:8766-76, which is incorporated herein by reference). The
active structures are described, with the restrictions and defi

nitions given below, by the formula:
25

Structures of some of the building blocks used for Z, X, Y,
Yand Aare shown in Formulae I-VIII above, which serves as
30

terms in the formula are defined as follows.

35

40

45

50

55

60

500 or more, in other embodiments, 200 or more and in
others, the SI is more than 100. In some cases the concentra

tions required to achieve a TDso may exceed the solubility
limits of the compounds. In these cases, calculation of an
exact SI will not be possible.
In some embodiments, polyamide sequences exhibiting
anti-RPV activity with the HPV types, especially, HPV 1, 6,

a glossary of terms. See also Table 1, below. The N-methyl
groups of the heterocycles I-, -P-and-Im- can be substituted
by N-ethyl and N-trifluoromethyl groups and the like. The
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Z is the N-terminal capping group and can be trifluoroac
etamide, acetamide, formamide (Lacy, et al. (2002) J. Am.
Chem. Soc. 124:2153-63, which is incorporated herein by
reference), propionamide, the so-calleddes-amino-imidazole
(denoted Im-, dI, des-Im or dIm, formula V)), and the like. Z
can also be represented by the formula Q-C(O)—, where Q is
selected from H. unsubstituted aliphatic, halo-aliphatic, Ca
aliphatic optionally Substituted with 1 or 2 amine groups, and
a heteroaryl optionally substituted with aliphatic or halo
aliphatic. The heteroaryl can be a fused bicyclic heteroaryl
with a 6.5 or 5.6 ring system.
X comprises the polyamide building blocks that include
primarily the 4-amino-2-carboxylic acid derivatives of N-me
thylpyrrole (-P-, formula I), beta-alanine (B), the 4-amino-2carboxylic acid derivative of N-methylimidazole (-I-, for
mula II), and substitutes for these groups, including C
aliphatic amino acids other than B-alanine. In one embodi
ment, the amino acids have an alpha-, omega-Substitution
pattern for the amino and acid groups. Other Substitutes for
these groups include natural alpha-amino acids such as gly
cine, and the amino acid derivatives of other heterocycles
(Nguyen, et al. (2001) Bioorg. Med. Chem.9:7-17; Zhan and
Dervan (2000) Bioorg. Med. Chem. 8:2467-2474, both of
which are incorporated herein by reference) or fused hetero
cycles (Briehn, et al. (2003) Chemistry—A European Journal
9:2110-2122; Marques, et al. (2004) J. Am. Chem. Soc. 126:
10339-10349; Phillion and Bashkin (2004), PCT Interna
tional Publication No. WO 04/099131; Renneberg and Der
van (2003) J. Am. Chem. Soc. 125:5707-5716, Tsai, et al.
(2007) Nucl. Acids. Res. 35:307-16; Buchmueller, et al.,
Nucl. Acids. Res. (2005) 33:912-21; Buchmueller, et al.
(2005).J. Am. Chem. Soc. 127:742-750; Nickols, et al. (2007)
Nucl. Acids Res. 33:363-70; Zhang, et al., J. Am. Chem. Soc.
(2006) 128:8766-76; Floreancig, et al., J. Am. Chem. Soc.
(2000) 122:6342-50; all of which are incorporated herein by
reference) that have been designed to mimic one or two pyr
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role and/or imidazole groups. Hence, X includes the groups
B-alanine (formula III), 4-amino-2-carbonyl-N-methylpyr
role (formula I), 4-amino-2-carbonyl-N-methylimidazole
(formula II), Caliphatic amino acids, natural C-amino

22
The formula Z (X)-y-CX), Y-A describes active mol
ecules under the following conditions:

acids, formula X1, formula X2, formula X3, formula X4,

Where imidazole-derived building blocks or their analogs
are incorporated only as about 0-10% of the sum of building
blocks 2+n+m; the number 2 accounts for the presence of Z
and Y as building blocks. Thus, for an active molecule with
2+n+m=22, there are typically about 0 to 2 imidazole groups
present, including their possible use as the Z group. m. can be
as large as 25, so that the total number of building blocks can

formula X5, formula X6, formula X7, and formula X8 (Table
1).
Y can be the gamma-aminobutyric acid building block
denoted Y (formula IV), the chiral analog of gamma-aminobu
tyric acid known as (R)-2,4-diaminobutyric acid (denoted
Y, formula VI) or its (S) isomer, and amide derivatives of
Y derived from trifluoroacetic acid, acetic acid, formic
acid, propionic acid, and the like. Hence, y' is selected from
Y-amino butyric acid (formula IV), (R)-2,4-diaminobutyric
acid (formula VI), (S)-2,4-diaminobutyric acid, formula Y1,
formula Y2, formula Y3, formula y4 (Table 1) and formula IX
(as well as the corresponding stereoisomer thereof),

Where m+3 is >11.
Where nm or m-1 or m-2.

10

be 50, 40, 30, 20, 15 or 10.
15

IX

w

NHR

where each R is independently selected from —C(O)—R
and each R is independently selected from H. unsubstituted
aliphatic, unsubstituted C-Caliphatic acyl, halo-aliphatic, a
natural cationic or neutral polar amino acid derived aminoa
cyl, and a C-C polyethylene glycol. When Y is 2,4-diami
nobutyric acid (either the (R) or (S) isomer), the 2-amino
group may be reacted into the polyamide to provide an alpha
turn or the 4-amino group may be reacted into the polyamide
to provide a gamma turn.
Y comprises -P- (formula I), -I- (formula II), beta-alanine
(formula III), other Caliphatic amino acids and the like,
where the amino and acids can be incorporated in an alpha-,
omega-Substitution pattern, and natural amino acids includ
ing glycine. Y also includes formula X7 (Table 1), Cali
phatic amino acids, and natural C.-amino acids.
A comprises a polar group that is cationic and taken from
the family exemplified by 3-dimethylamino-propylamine
(Dp, formula VII), 3,3'-diamino-N-methyldipropylamine
(Ta, formula VIII) and related linear and cyclic aliphatic
amines, oligoamines and polyamines. “A” may also be cho
Sen from amidines, guanidines, secondary ammonium salts,
Sulfonium salts, phosphonium salts and other cationic C-ter
minal groups found in DNA-binding polyamides and in the
related natural products distamycin A, netropsin and the like.

25

2006:ORGN-678; Dervan, et al. PCT International Publica

tion No. WO 04/078943; Nguyen, et al. (2001) Bioorg. Med.
Chem. 9:7-17; Phillion and Bashkin PCT International Pub
30
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Hence. A can include formula A1, formula A2, formula A3,
formula A4, formula A5, formula A6, formula A7, formula

A8, formula A9, formula A10, formula A11 (Table 1), and

Where a beta-alanine occurs such that the longest group of
contiguous heterocyclic building blocks is about 4, beta-ala
nine occurs after one, two, three or four contiguous Pand/or
I building blocks as exemplified by -P-P-P-P-3 and I-P-P-3.
In one embodiment, beta-alanine occurs after every three or
four contiguous heterocycles.
Where certain fused heterocycles or other heterocycles
may be used sparingly to replace-P-, I- or-I-building blocks
Z and X, as previously described for DNA-binding polya
mides that comprise largely -P-, I-and-I-groups (Briehn, et
al. (2003) Chemistry—A European Journal 9:2110-2122;
Buchmueller, et al. (2006) Abstracts of Papers, 231st ACS
National Meeting, Atlanta, Ga., United States, Mar. 26-30.
lication No. WO 04/099 13 1: Renneberg and Dervan (2003)
J. Am. Chem. Soc. 125:5707-5716; Turlington, et al. (2006)
Heterocyclic Communications 12:89-92; Uthe, et al. (2005)
Heterocyclic Communications 11:163-166; Zhanand Dervan
(2000) Bioorg. Med. Chem. 8:2467-2474, all of which are
incorporated herein by reference). In Such cases, aliphatic
amino acids, including the alpha-, -omega-amino acids beta
alanine or Y and the like, will occur after 2-4 (or after 3 or 4)
contiguous replacements for building blocks-Py-, -I- or Im-.
Thus, in one aspect, the total number of 4-amino-2-carbo
nyl-N-methylimidazole (formula II) units in Z (X),y(X), Y-A is less than 0.10x(m+n+2).
In another aspect, any B-alanine (formula III) unit in
Z—CX)-Y7-(X), Y-A is adjacent to at least three contigu
ous units of 4-amino-2-carbonyl-N-methylpyrrole (formula
I), at least three contiguous units 4-amino-2-carbonyl-N-me
thylimidazole (formula II), or at least three contiguous units
of any combination of 4-amino-2-carbonyl-N-methylpyrrole
(formula I) and 4-amino-2-carbonyl-N-methylimidazole
(formula II).
In another embodiment, the compound has the formula
or a pharmaceutically acceptable salt thereof, wherein m+3 is
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at least 7; and the other substituents are as described above.

In still another embodiment, the compound has the for
mula:

60

or a pharmaceutically acceptable salt thereof, wherein
m is 10 or 11;
n is 9 or 10;
Im is desamino-imidazole;

65

wherein each R is independently Cisaliphatic.

each X is independently selected from 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-me
thylpyrrole (P) or B-alanine (B), subject to the proviso
that the compound contains no more than two I units;
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ImPPPBPPPBPPyPPPBPPPBPPPBTa;
Y is Y-aminobutyric acid (Y), (S)-2,4-diaminobutyric acid,
(R)-2,4-diaminobutyric acid (Y), (S)-2-(acety
ImPPBPPIBPPYPPBPPPBPPPBTa:
ImPPBPPIBPPYPPBPPPBPPPBDp;
lamino)-4-aminobutyric acid, or (R)-2-(acetylamino)-4ImPPBPPIBPPYPPBPPPBPPPBDp;
aminobutyric acid (Yv);
Y is f-alanine ((3) or 4-amino-2-carbonyl-N-methylpyr
ImPPBPPIBPPYPPBPPPBPPPBTa:
ImPPBPPIBPPYPPBPPPBPPPBDp;
role (P); and
ImPPBPPIBPPyPPBPPPBPPPPTa; or
A is 3,3'-diamino-N-methyldipropylamine (Ta) or dim
ethylaminopropylamine (Dp).
ImPPBPPPyPPBPPPPPTa;
The sequence—CX) may, for example, be selected from or a pharmaceutically acceptable salt thereof;
the group consisting of -PPBPPIRPP-, -PPBPIPBPPI-, and 10 wherein:
-PPPBPPPBPP-. The sequence —(X), Y may, for
Im is desamino-imidazole;
example, be free of Iunits and may be selected from the group
P is 4-amino-2-carbonyl-N-methylpyrrole;
consisting of -PPBPPPBPPPB-,-BPBPPPBPPPB-, -PPPBPPB is B-alanine;
PBPPPB-, and -PPBPPPBPPPP-.
I is 4-amino-2-carbonyl-N-methylimidazole;
Examples of specific compounds within the scope of the 15 Y is Y-aminobutyric acid,
invention include:
ImPPBPPIBPPyPPBPPPBPPPBDp;
ImPPBPPIBPPyPPBPPPBPPPBTa;
ImPPBPIPBPPIy?3PBPPPBPPPBTa;
ImPPPBPPPBPPyPPPBPPPBPPPBDp;

Y

is (R)-2,4-diaminobutyric acid reacted through either
the 2-amino group or the 4-amino group;
Y
is (R)-2-(acetylamino)-4-aminobutyric acid;
Ta is 3,3'-diamino-N-methyldipropylamine; and
Dp is dimethylaminopropylamine.
TABLE 1

Polyamide Building Blocks
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TABLE 1-continued
Polyamide Building Blocks
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Polyamide Building Blocks
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Polyamide Building Blocks
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TABLE 1-continued
Polyamide Building Blocks

X-sh

HN

O
A1O

NH

N

CH3 HNCH
A11

--\ /Y

X,

1n 1\ N 1N1-S-N2
H

spermidine (a)

--~~~~
spermidine (b)

H
HN

1n 1a N 1S-1S-N-1 n- NH2

--

H
Spermine
Aliphatic di-or
polyamines of the
formula NH2CH2
(NH2), where d =
2-6 and e = 2-6.

Components Z, X, Y and A can include heteroaromatic
fused bicyclic structures (i.e., where one of the rings thereof
is heteroaromatic and the other is aromatic or heteroaro

matic). These are described in PCT International Publications
WO 04/099131 and WO 05/033282, both of which are incor
porated herein by reference. This structure can act as a hydro

gen bond acceptor to bind guanine in the minor groove of

double stranded DNA and the structure cannot form a tau
tomer in which the heteroatom becomes an H-bond donor.

50

moiety (e.g., a pyrrole or imidazole ring). Accordingly, the
addition of each fused, bicyclic structure in the polyamide
enables the elimination of an H-bond donor (e.g., an amido
linker oramido containing moiety). Thus the polyamides are
capable of altered or enhanced interactions in the minor
groove of DNA. An exemplary embodiment of a fused bicy
clic structure is

The bicyclic compounds may contain linking moieties Such
as amide oramide-containing linking moieties. Accordingly,
in one embodiment, the compound may comprise a series of 60
at least about 2, 4, 6, 8, 10 or more cyclic moieties (e.g.,
N---- (----X,
heterocyclic, including heteroaromatic moieties and fused
bicyclic structures as described herein) which are bound with
one or more linking moieties, to form complementary pairing in which X, X and X are independently further described
65 below and provided X is an H-bond acceptor heteroatom,
with nucleotides of the dsDNA.
In one embodiment, the fused bicyclic structure is directly each ring of the fused bicyclic structure is unsaturated and has
bound to another fused bicyclic structure or a heterocyclic 5 or 6 members, except that both rings do not have 5 members.

US 8,993,609 B2
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The dotted lines in the above structure indicate that the rings

36

are unsaturated, aromatic or heteroaromatic.

X

(

The fused bicyclic structure that serves as an H-bond
acceptor in the compound may be characterized, in one

N2

COOH

embodiment as

where X=S or N CH.
In another embodiment, the first ring of the fused bicyclic
structure is
10

21

X

where X and X are independently selected from O, S, N,

NNR, CR, CR-CR", N=N and CR: provided that (i)

when each one of X or X is independently selected from

N
15

CR or Nand (ii) when each one of X or X is independently
selected from CR-CR, CR-N, N–CR or N-N, the
other is independently selected from CR' or N; X is inde
pendently selected from N, O, S, CR, NR, CR =CR,
CR=N, N=CR and N=N, and X is independently
selected from O, S, N and CH, provided that (i) when each X
is independently selected from CR or N, X is independently

where X=S or N CH.
In another embodiment, the compound has the formula:
or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 8 and the other substituents are as described above.

In another embodiment, the invention provides a com
pound comprising the formula

selected from O or S and (ii) when each X is independently

selected from O, S, NR, CR-CR, CR-N,N-CR or
N=N, X is independently selected from CH or N; and each

25

R substituent (i.e., R. R. R", R. R) generally represents

an H or some other substituent which does not detrimentally
hinder binding of the compound to the dsDNA or, alterna
tively acts to enhance binding, provided that the structure
cannot form a tautomer in which the heteroatom for binding
guanine becomes an H-bond donor (e.g., when X or X is

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 11 and the other substituents are as defined above.
30

NR, R is other than Hand when X is NR, R is other than
H).
The dotted lines in the above structure indicate that the

rings are unsaturated (aromatic or in the case of a heteroatom
containing ring, heteroaromatic). Acceptable Substituents
(e.g., R) may include, for example, those independently
selected from H., hydroxy, N-acetyl, benzyl, substituted or
unsubstituted C. alkyl, substituted or unsubstituted C
alkyl amine, Substituted or unsubstituted C. alkyldiamine,
Substituted or unsubstituted C. alkylcarboxylate, Substi
tuted or unsubstituted C- alkenyl, Substituted or unsubsti
tuted C-alkynyl, and the like, and when attached to a carbon
optionally halo.
In instances or embodiments where the first ring of the
fused bicyclic structure is heteroaromatic and the structure
occupies an initial terminal (i.e., 'cap') position X may be

35

In aspects of the embodiments, y' is (R)-2,4-diaminobu
tyric acid (formula VI), and in another aspect, y' is Y-amino
butyric acid (formula IV).
In other aspects of the embodiments where the compound
corresponds to formula Z-CX)-y-CX), Y-A, m is an inte
ger between 8 and 11, and in another aspect where the com
pound corresponds to formula Z (X)-Y7-(X), Y-A, n is
an integer between 6 and 10.
In yet another aspect of the embodiments, Y is 3-alanine.
In still another aspect of the embodiments, m is no larger
than 25.

40

45

for example, C H when X is NR (e.g., N CH). Accord

ingly, when the fused, bicyclic structure serves as a cap the
carbon present between X and X is typically the point of
attachment of the second ring to the remaining portion of the
compound. In Such instances the structure may be repre
sented, for example, as:

N

50
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Polyamides of the invention include the compounds
ImPPBPIPBPPYPPBPPPBPPPBTa,
ImPPBPPPYPPBPPPPRTa, ImPPPBPPByPPBPPPBPBTa,
ImPPPBPPBYPPBPPPBPBTa, ImPPPBPPPyPPPBPP
PBBTa, ImPPBPPPyPPBPPPPBTa, ImPPBPPPyPPBPPPPTa,
ImPPBPPPYPPBPPPPBTa, ImPPBPPPYPPBPPP
PBTa,
ImPPPBPPBYPPBPPPBPBDp,
ImPPPBPPBPPPPPPPPPPPPPPRDp, ImPPBPPPyPPB
PPPPBDp,
ImPPPBPPBPPPyPPPBBPPPBPPPBDp,
ImPPPBPPPPPPPPPPRBDp,
ImPPBPPPYPPBPPPPBDp,
ImPPPBPPPYPPPBPPPBBTa,
ImPPBPIPBPPYPPBPPPBPPPBDp,
ImPPBPPBPIYPBPPBPPPBPBDp, and ImPPPBPPByPPB
PPPBPBDp, wherein Im is desamino-2-carbonyl-N-methyl
imidazole (formula V), P is the 4-amino-2-carboxylic deriva
tive of N-methylpyrrole (formula I), Dp is
dimethylaminopropylamine (formula VII), B is B-alanine
(formula III), I is the 4-amino-2-carboxylic derivative of
N-methylimidazole (formula II) and Ta is 3,3'-diamino-Nmethyldipropylamine (formula VIII).
The chemical structure of a representative polyamide of the
invention is shown in FIG. 6.

where the bond extending from the noted sp’ hybridized
carbon serves to connect the structure to the remaining por
tion of the compound.
In one embodiment, the first ring of the fused bicyclic
structure is:
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The present invention also includes analogs that lack a
B-alanine at the C-terminal position and analogs that have an
acetylated diamino Y turn, as these may improve cellular
uptake and nuclear localization (Best, et al. (2003) Proc. Natl.
Acad. Sci. USA, 100:12063-68; Crowley, et al. (2003) PCT
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International Publication No. WO 03/041128; Crowley, et al.
(2003) Bioorg. Med, Chem. Lett. 13:1565-70; Edelson, et al.
(2004) Nucl. Acids Res. 32:2802-18; all of which are incor
porated herein by reference).
In other embodiments, the polyamides can be modified by
one or more of the following: (1) eliminating the beta-alanine
that links the polyamide to the cationic diamine tail Dp; (2)
using triamine (Ta) cationic tails to access active spermidine
uptake pathways; and (3) lowering the isoelectric point of
polyamides (standard abbreviation: pl) to diminish their

10

accumulation in acidic vesicles. In some embodiments, the

38
In Solution-phase polyamide synthesis, two main amide
bond forming routes may be used: (1) the haloform reaction
and (2) reactions of amines with acids in the presence of
coupling agents like DCC, EDC or HATU (when required).
For our heterocyclic building blocks, the haloform reaction
can be the method described in Xiao et al., (2000) Chin. J.
Chem, 18:603-07 and Xiao et al., (2000) J. Org. Chem.
65:5506-13, (both of which are incorporated herein by refer
ence) because the relevant trichloroketone can be made
directly from trichloroacetylchloride and the heterocycle
(Scheme I).

polyamides are altered with all of the modifications 1, 2 and
3.

Scheme I: The Haloform Reaction-preparation of starting material and

In yet other embodiments the polyamides contain, at the
C-terminal end, FITC (Fluorescein Isothiocyanate),
BODIPY or another compound that can be used to determine
cellular localization. In some embodiments, polyamides con
taining FITC at the C-terminal end are more readily taken up
by cells.
In still other embodiments, in addition to forming hairpin
structures, the polyamides can form dimers, some of which

15

use in Dimer Formation

ON

N

N

HN

25

ON

HPV 16, HPV11, HPV6, HPV31 or HPV1.

In further embodiments, the polyamides target DNA
viruses, which include Epstein-Barr virus, herpes virus, pox

ye. As
II.
ClCC(O)Cl

are connected, as shown in FIG. 8. Thus, one can make

analogs of active hairpins using these alternative polyamide
motifs described by Dervan. See, e.g., Dervan and Edelson
(2003) Curr. Opin. Struct. Biol. 13:284-99, which is incorpo
rated herein by reference.
In even other embodiments, the polyamides target HPV 18,

ON

30

O

ON

viruses and other double-stranded DNA viruses. Possible

targets within these viruses may include sequences required
for tethering, maintenance, or replication.
B. General Synthetic Schemes
The polyamides as described herein may be commercially
available or produced from known starting materials by
known methods. See for example WO 05/033282, Belitsky et
al., (2002) Bioorg. Med. Chem., 10, 2767-74; Zhang, et al.
(2006).J. Am. Chem. Soc. 128:8766-76: Turner, et al. (2001)
Organic Letters, 3:1201-03, all of which are incorporated
herein by reference.
Polyamides can be prepared using manual Solid-phase syn
thesis as well as automated Solid-phase chemistry. Each cou
pling is followed by HPLC and HPLC/mass spectrometry
(MALDI mass spectrometry was used when the MW
exceeded 1500; more recently, multiply-charged ions in elec
trospray mass spectrometry are employed when the MW
exceeds 3000).

-N-1 n-N

rty
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The steps in Scheme I would be followed by reduction of
the nitro group with H and Pd/C. The resulting free amino
group can be protected or immediately coupled to an addi
tional building block. The use of solution methods to make an
entire polyamide is illustrated in Scheme II. Common build
ing blocks can be identified for a polyamide, allowing effi
cient solution phase synthesis: the P P dimer can be made
and purified on a large scale and then used directly or elabo
rated further as in Scheme II to form the major sections of the
target sequence, and then the final product.

R
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H
--

O

NH
-

+ 3

O
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-

-O

O

-
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Scheme II shows a scale-up strategy based on solution
phase assembly of an active polyamide from trimer and
monomer building blocks. The common P P unit can be
elaborated to form the entire molecule. Additional pyrroles
are shown. Additional 3-alanines are shown, and the N-Balanine-P P P fragment is seen to occur twice in the mol
ecule (indicated by Square brackets). Three final unique frag
ments are also shown. See e.g., Xiao, et al., J. Org. Chem.
(2000) 65:5506-13, which is incorporated herein by refer

35

salts as well as chloride. Succinate, ascorbate salts and the

40

CCC.

Another method for producing a pyrrole-imidazole polya
mide is described in US Patent Publication No. US 2004/

0171799, which is incorporated herein by reference.
Yet another method of synthesis is to prepare a polyamide
oligomer starting with Boc?B-alanine-WANG solid phase syn
thesis resin, or a similar commercially available resin, adding
building blocks as required for the target sequence. (See
Example 8.)
The structures of polyamide compounds were character
ized with, for example, MALDI mass spec after each unit was
added and after the final synthetic step. The measurements
were performed at Global Peptide (Fort Collins Colo.).
Polyamides can be purified to 98% or better purity by pre
parative HPLC (sometimes requiring a second prep HPLC
run). Combined HPLC fractions of the final product after
analytical HPLC and mass spectra (MALDI) showed both the
presence of the final product and the absence of failure

45
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Sequences.
60

V. Pharmaceutical Compositions
A. Formulation

In another aspect of the present invention, pharmaceuti
cally acceptable compositions are provided, wherein these
compositions comprise any of the compounds as described
herein, and optionally comprise a pharmaceutically accept

able carrier, adjuvant or vehicle. In certain embodiments,
these compositions optionally further comprise one or more
additional therapeutic agents.
Polyamides can be in the form of trifluoroacetate (TFA)

65

like. They can also be formulated with excipients such as
PEG-400, propylene glycol and the like.
To increase stability, the polyamide drug will be placed in
aqueous Solution with an antioxidant Such as ascorbic acid,
BHT and BHA in order to develop a more stable formula.
(See Mayers CL, et al. (1993) Pharma Res, 10:445-448, and
Stuhar M, (1984) Farmaceuticky Obzor, 53:499-504, both of
which are incorporated herein by reference.)
For delivery to the vagina and cervix, polyamides will be
formulated in Solutions, emulsions, Suspensions, tablets, gels,
foams, Suppositories, films, sponges and vaginal rings. For
mulations include gels (e.g. hydroxyethylcellulose and poly
acrylic acids, e.g. Carbopols), and polyvinyl alcohol films
that can be administered by an applicator to the target site.
Alternatively, lower viscosity liquid formulations (e.g. PEG
Solutions) can be delivered in a polyurethane sponge to the
area around the cervix. (Okada, (1991) in “Peptide and Pro
tein Drug Delivery V. H. Lee, ed., pp. 663-666, Marcel
Dekker, NY: Garg, et al. (2001) Pharm. Tech. 25:14-24, both
of which are incorporated herein by reference.) Because of
polyamides charge, the polyamides may be formulated in a
controlled delivery vehicle by using the Carbopols. If the
polyamide has a charge of +1 or +2, by adjusting the ionic
strength of the formulation one may bind the polyamide elec
trostatically to the Carbopol and thereby control the release
rate. In all semisolid dosage forms that produce chemically
and physically stable PAs, we will evaluate the release rate in
a membrane apparatus as described in the US Pharmacopeia
(Dipiano, et al., PCT International Publication No. WO
04/064913, which is incorporated herein by reference) for
drug diffusion from semisolid dosage forms. Polyamides for
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mulated in Carbopol-based gels which exhibit significant numerous other applicators and formulas that have been
yield stresses, and also have potential bioadhesive properties developed for controlled vaginal drug delivery (Robinson
(Kieweg, et al. (2004) J. Pharm Sci. 93, 2941-52, which is (1999) Proc. Of the 26" Intl. Symp. Controlled Release of
incorporated herein by reference).
Bioactive Materials, 26:2-3, which is incorporated herein by
Formulae in Table 2 were chosen to evaluate a range of 5 reference; Hussain and Ahsan, 2005).
excipients used for commercial vaginal formulations (Garget
Formulations for transdermal delivery include lipid-based
al., 2001). A number of commonly used excipients such as formulas for delivery of protein pharmaceuticals to genital
PEG (polyethyleneglycol), PVA (polyvinyl alcohol) and warts (Foldvari et al., (1999), Biotech. Appl. Biochem.
Tween R surfactants can also be added. In addition to antioxi
30:129-37; Leigh (2003) Drugs and the Pharm. Sci., 126:791
dants, further compatabilizers or stabilizers may be used. 10 800; Lee et al., (2004) Biomaterials, 26:205-10, all of which
Solid forms may allow for more stable formulas with a longer are incorporated herein by reference), bioadhesives formula
shelf life due to their physical state. Emulsions made from tions (Bogataj and Mrhar (1998) Bioadhesive mucosal drug
bioadhesives using polymers such as Carbopol may be useful. delivery systems, 49:445-57; Amaral et al. (1999) Contracep
HPMC (hydroxymethylpropyl cellulose). PVA and lipid tion, 60:361-66; Barry, (1987) in “Drug Delivery systems',
complexes can be also used with lower solubility drugs. Lip 15 Johnson and Lloyd-Jones, eds, Ch. 11, Ellis Horwood, Chich
idic systems may then be suspended in a viscoelastic gel for ester; Vermani, et al. (2002) Drug Dev. Indust. Pharm.
delivery of the insoluble polyamide.
28: 1133-46, all of which are incorporated herein by refer
TABLE 2

First Generation Formulas for Transdermal Deliveryo
Polyanides to Raft Cultures and the Rabbit Cervix
Prototype

Concentration or

formula

Excipients + API

Solution

Polyamide, DMSO, water,

other variable(s)

Polyamide

BHT

Eventual delivery
evice

Vaginal syringe,
Polyurethane
Sponge,

Solution

Polyamide, DMSO, PEG

Polyamide and
MW of PEG

Cotton applicator
Vaginal syringe,
Polyurethane

sponge, cotton

applicator
bioadhesive

Polyamide in

Polyamide

polycarbophil
Film

Film

Gel

Polyamide in PEG 400
and PEG fatty acid esters,

Polyamide),
PEG 400 and

Tween (R 80 and minimal
DMSO
Polyamide, minimum

PEG fatty acid
esters
Polyamide

DMSO, Polyvinyl alcohol
Polyamide, Carbopol
974; Polyamide and

Solid or emulsion

delivery
applicator
Vaginal syringe

Solid insert

Polyamide

Gel applicator

Polyamide

Gel applicator

Carbomer 94.34P and

tablet

polycarbophil
Polyamide and colloidal
Silicon dioxide,

tablet

Corn starch, lactose,

liposome

magnesium Stearate, 1
vinyl-2 pyrrollidone
Polyamide,
phosphatidylcholine,

or solid insert

Polyamide

composition

insert

Syringe applicator

addtitives such as

Tween (R 80, cholates,
DMSO

For more sustained or effective delivery, cervical barrier
devices available Such as diaphragms that can deliver the drug
at the cervix site over many hours can be used. For even more
continuous delivery, vaginal rings or slow release implantable
polymer films can be employed. In addition, several new
vaginal delivery systems in clinical testing Such as vaginal
sponge technology and the SILCS diaphragm, a single size
silicone device that can deliver drug to both the cervix and
vaginal wall (Cohen, (2004) The Microbiocide Quarterly,
2:15-19, which is incorporated herein by reference) may be
used. For improved continuous delivery of the drug over an
extended period of time, vaginal rings are available with slow
release of the drug from the ring composite (Cohen, 2004:
Hussain and Ahsan, (2005), J. Controlled Release 103:301
13, which is incorporated herein by reference). There are also
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ence) and novel polymer systems. The novel polymers
include partially absorbable biodegradable antiviral intrav
aginal rings (Shalaby, (2005) U.S. Patent Application Publi
cation No. 2005/053639, which is incorporated herein by
reference), bilaminar bioadhesive polymeric films applied
directly to the cervix (Sidhu et al., (1997) Br. J. Obstetrics and
Gynaecology, 104:145-49, which is incorporated herein by
reference) novel, slow-release polymer discs at the cervical
mucosa and thermogelling systems that have the advantage of
potentially much greater bioadhesion and dosage form reten
tion. (Saltzman and Radomsky (1990) Polymer Preprints,
31:245-46; Edelman and Mark (1998) Nature Biotech,
16:136-37, both of which are incorporated herein by refer
ence). Polyamides may also be formulated using cell mem
brane penetrating peptides (Gupta, et al. (2005) Adv. Drug
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Del Rev. 57:637-51; Wadia and Dowdy (2005) Adv. Drug
Del. Rev., 57:579-96, both of which are incorporated herein
by reference).
Polyamides can also be formulated with a pharmaceuti
cally-acceptable polymer designed to lengthen time before
renal clearance.

Polyamides can also be formulated to deliver an aerosol
treatment of the lungs.
It will also be appreciated that certain compounds of
present invention can exist in free form for treatment, or
where appropriate, as a pharmaceutically acceptable deriva
tive or a prodrug thereof. According to the present invention,
a pharmaceutically acceptable derivative or a prodrug
includes, but is not limited to, pharmaceutically acceptable
salts, esters, salts of such esters, or any other adduct or deriva
tive which upon administration to a patient in need is capable
of providing, directly or indirectly, a compound as otherwise

10

Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin

15

described herein, or a metabolite or residue thereof.

As used herein, the term “pharmaceutically acceptable
salt” refers to those salts which are, within the scope of sound
medical judgment, Suitable for use in contact with the tissues
of humans and lower animals without undue toxicity, irrita
tion, allergic response and the like, and are commensurate
with a reasonable benefit/risk ratio. A “pharmaceutically
acceptable salt' means any non-toxic salt or salt of an ester of
a compound of this invention that, upon administration to a
recipient, is capable of providing, either directly or indirectly,
a compound of this invention oran inhibitorily active metabo
lite or residue thereof.

Pharmaceutically acceptable salts are well known in the
art. For example, S. M. Berge, et al. describe pharmaceuti
cally acceptable salts in detail in J. Pharmaceutical Sciences,
1977, 66, 1-19, incorporated herein by reference. Pharmaceu
tically acceptable salts of the compounds of this invention
include those derived from Suitable inorganic and organic
acids and bases. Examples of pharmaceutically acceptable,
nontoxic acid addition salts are salts of an amino group
formed with inorganic acids such as hydrochloric acid,
hydrobromic acid, phosphoric acid, Sulfuric acid and perchlo
ric acid or with organic acids such as acetic acid, including
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trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid,

citric acid, Succinic acid or malonic acid or by using other
methods used in the art such as ion exchange. Other pharma
ceutically acceptable salts include adipate, alginate, ascor
bate, aspartate, benzenesulfonate, benzoate, bisulfate, borate,
butyrate, camphorate, camphorsulfonate, citrate, cyclopen
tanepropionate, digluconate, dodecylsulfate, ethane
Sulfonate, formate, fumarate, glucoheptonate, glycerophos
phate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lac
tate, laurate, lauryl Sulfate, malate, maleate, malonate, meth
anesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
Stearate. Succinate, Sulfate, tartrate, thiocyanate, p-toluene
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(Mack Publishing Co., Easton, Pa., 1980) discloses various
carriers used in formulating pharmaceutically acceptable
compositions and known techniques for the preparation
thereof. Except insofar as any conventional carrier medium is
incompatible with the compounds of the invention, Such as by
producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other
component(s) of the pharmaceutically acceptable composi
tion, its use is contemplated to be within the scope of this
invention. Some examples of materials which can serve as
pharmaceutically acceptable carriers include, but are not lim
ited to, ion exchangers, alumina, aluminum Stearate, lecithin,
serum proteins, such as human serum albumin, buffer Sub
stances such as phosphates, glycine, Sorbic acid, or potassium
Sorbate, partial glyceride mixtures of Saturated vegetable
fatty acids, water, salts or electrolytes, such as protamine
Sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, Sodium chloride, Zinc salts, colloidal silica, mag
nesium trisilicate, polyvinyl pyrrolidone, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers,
wool fat, sugars such as lactose, glucose and sucrose; starches
Such as corn starch and potato starch; cellulose and its deriva
tives such as sodium carboxymethylcellulose, ethyl cellulose
and cellulose acetate; powdered tragacanth; malt, gelatin:
talc, excipients such as cocoa butter and Suppository waxes;
oils such as peanut oil, cottonseed oil; Safflower oil; Sesame
oil; olive oil; corn oil and soybean oil; glycols; Such as pro
pylene glycol or polyethylene glycol; esters such as ethyl
oleate and ethyl laurate; agar, buffering agents such as mag
nesium hydroxide and aluminum hydroxide; alginic acid;
pyrogen-free water, isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer Solutions, as well as other non
toxic compatible lubricants such as sodium lauryl Sulfate and
magnesium Stearate, as well as coloring agents, releasing
agents, coating agents, Sweetening, flavoring and perfuming
agents, preservatives and antioxidants can also be present in
the composition, according to the judgment of the formulator.
According to the invention an “effective amount of the
compound or pharmaceutically acceptable composition is
that amount effective for treating or lessening the severity of
HPV infections.
B. Administration
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Sulfonate, undecanoate, Valerate salts, and the like. Salts

derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N(Calkyl) salts. This inven
tion also envisions the quaternization of any basic nitrogen
containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersable products may be obtained by
Such quaternization. Representative alkali or alkaline earth
metal salts include sodium, lithium, potassium, calcium,
magnesium, and the like. Further pharmaceutically accept
able salts include, when appropriate, nontoxic ammonium,
quaternary ammonium, and amine cations formed using
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counterions such as halide, hydroxide, carboxylate, Sulfate,
phosphate, nitrate, lower alkyl Sulfonate and aryl Sulfonate.
As described above, the pharmaceutically acceptable com
positions of the present invention additionally comprise a
pharmaceutically acceptable carrier, adjuvant, or vehicle,
which, as used herein, includes any and all solvents, diluents,
or other liquid vehicle, dispersion or Suspension aids, Surface
active agents, isotonic agents, thickening or emulsifying
agents, preservatives, Solid binders, lubricants and the like, as
Suited to the particular dosage form desired. Remington's
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The pharmaceutical compositions, according to the
method of the present invention, may be administered using
any amount and any route of administration effective for
treating or lessening the severity of a chronic HPV disease.
The exact amount required will vary from subject to sub
ject, depending on the species, age, sex, weight, diet, medical
condition and general condition of the Subject, the severity of
the infection, the particular agent, its mode of administration,
and the like. Other factors affecting the dosing regimen
include pharmacological considerations such as the activity,
efficacy, pharmacokinetics and toxicology profiles of the
compounds employed, whether a drug delivery system is
used and whether the compounds are administered with other
ingredients. The dosage can be determined routinely using
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standard methods known in the art. The dosage regimenactu
ally employed may therefore vary widely based upon the
treated Subject and thus deviate from the exemplary dosage
regimen set forth below. The compounds of the invention are
preferably formulated in dosage unit form for ease of admin
istration and uniformity of dosage. The expression "dosage
unit form as used herein refers to a physically discrete unit of
agent appropriate for the patient to be treated. It will be
understood, however, that the total daily usage of the com
pounds and compositions of the present invention will be
decided by the attending physician within the scope of sound
medical judgment. The specific effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed:
the specific composition employed; the age, body weight,
general health, sex and diet of the patient; the time of admin
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preparation may also be a sterile injectable solution, Suspen
sion or emulsion in a nontoxic parenterally acceptable diluent
or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be
employed are water, Ringer's solution, U.S.P. and isotonic
sodium chloride solution. In addition, sterile, fixed oils are
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istration, route of administration, and rate of excretion of the

specific compound employed; the duration of the treatment;
drugs used in combination or coincidental with the specific
compound employed, and like factors known in the medical
arts. The term “patient’, as used herein, means an animal, for
example, a mammal, or a human.
Administration of the compounds may be with a regimen
calling for a single daily dose, multiple, spaced doses
throughout the day, a single dose every other day, a single
dose every several days or other appropriate regimens.
For example, the formulated polyamides can be adminis
tered once daily at a final concentration of 5 mg/mL (approxi
mate concentration of 2.5 mM) in approximately 4 ml of
vehicle via a vaginal applicator, for example, to the posterior
fornix of the vagina. If administered in the evening prior to
sleep, it is anticipated that most of the drug will remain in the
highest aspects of the vaginal canal, in closest proximity to
the cervix, due to lack of ambulation. In one embodiment, the
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polyamide formulation will be administered for 10 days.
The pharmaceutically acceptable compositions of this
invention can be administered to humans and other animals

orally, rectally, parenterally, intracisternally, intravaginally,
intraperitoneally, topically (as by powders, ointments, or
drops), bucally, as an oral or nasal spray, or the like, depend
ing on the severity of the infection being treated. In certain
embodiments, the compounds of the invention may be admin
istered orally or parenterally at dosage levels of about 0.01
mg/kg to about 50 mg/kg and preferably from about 1 mg/kg
to about 25 mg/kg, of Subject body weight per day, one or
more times a day, to obtain the desired therapeutic effect.
Liquid dosage forms for oral administration include, but
are not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, Suspensions, syrups and elixirs.
In addition to the active compounds, the liquid dosage forms
may contain inert diluents commonly used in the art Such as,
for example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol. 1,3-butylene glycol, dimethylformamide,
oils (in particular, cottonseed, groundnut, corn, germ, olive,
castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol,
polyethylene glycols and fatty acid esters of Sorbitan, and
mixtures thereof. Besides inert diluents, the oral composi
tions can also include adjuvants such as wetting agents, emul
Sifying and Suspending agents, Sweetening, flavoring, and
perfuming agents.
Injectable preparations, for example, Sterile injectable
aqueous or oleaginous Suspensions may be formulated
according to the known art using Suitable dispersing or wet
ting agents and Suspending agents. The sterile injectable
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conventionally employed as a solvent or Suspending medium.
For this purpose any bland fixed oil can be employed includ
ing synthetic mono- or diglycerides. In addition, fatty acids
Such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by incor
porating sterilizing agents in the form of sterile solid compo
sitions which can be dissolved or dispersed in sterile water or
other sterile injectable medium prior to use.
To prolong the effect of a compound of the present inven
tion, it is often desirable to slow the absorption of the com
pound from Subcutaneous or intramuscular injection. This
may be accomplished by the use of a liquid Suspension of
crystalline or amorphous material with poor water solubility.
The rate of absorption of the compound then depends upon its
rate of dissolution that, in turn, may depend upon crystal size
and crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished
by dissolving or Suspending the compound in an oil vehicle.
Injectable depot forms are made by forming microencapsule
matrices of the compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of com
pound to polymer and the nature of the particular polymer
employed, the rate of compound release can be controlled.
Examples of other biodegradable polymers include poly
(orthoesters) and poly(anhydrides). Depot injectable formu
lations are also prepared by entrapping the compound in
liposomes or microemulsions that are compatible with body
tissues.

Compositions for rectal or vaginal administration can be
Suppositories which can be prepared by mixing the com
pounds of this invention with Suitable non-irritating excipi
ents or carriers such as cocoa butter, polyethylene glycol or a
Suppository wax which are solid at ambient temperature but
liquid at body temperature and therefore melt in the rectum or
vaginal cavity and release the active compound.
Solid dosage forms for oral administration include cap
Sules, tablets, pills, powders, and granules. In Such solid dos
age forms, the active compound is mixed with at least one
inert, pharmaceutically acceptable excipient or carrier Such as
Sodium citrate or dicalcium phosphate and/or (a) fillers or
extenders such as starches, lactose, Sucrose, glucose, manni
tol, and silicic acid, (b) binders such as, for example, car
boxymethylcellulose, alginates, gelatin, polyvinylpyrrolidi
none. Sucrose, and acacia, (c) humectants such as glycerol,
(d) disintegrating agents such as agar-agar, calcium carbon
ate, potato or tapioca starch, alginic acid, certain silicates, and
Sodium carbonate, (e) solution retarding agents such as par
affin, (f) absorption accelerators such as quaternary ammo
nium compounds, (g) wetting agents such as, for example,
cetyl alcohol and glycerol monostearate, (h) absorbents such
as kaolin and bentonite clay, and (i) lubricants such as talc,
calcium Stearate, magnesium Stearate, Solid polyethylene gly
cols, Sodium lauryl Sulfate, and mixtures thereof. In the case
of capsules, tablets and pills, the dosage form may also com
prise buffering agents.
Solid compositions of a similar type may also be employed
as fillers in Soft and hardfilled gelatin capsules using Such
excipients as lactose or milk Sugar as well as high molecular
weight polyethylene glycols and the like. The Solid dosage
forms of tablets, dragees, capsules, pills, and granules can be
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prepared with coatings and shells Such as enteric coatings and
other coatings well known in the pharmaceutical formulating
art. They may optionally contain opacifying agents and can
also be of a composition that they release the active ingredient
(s) only, or preferentially, in a certain part of the intestinal
tract, optionally, in a delayed manner. Examples of embed
ding compositions that can be used include polymeric Sub
stances and waxes. Solid compositions of a similar type may
also be employed as fillers in soft and hardfilled gelatin cap
Sules using Such excipients as lactose or milk Sugar as well as
high molecular weight polethylene glycols and the like.
The active compounds can also be in microencapsulated
form with one or more excipients as noted above. The solid
dosage forms of tablets, dragees, capsules, pills, and granules
can be prepared with coatings and shells Such as enteric
coatings, release controlling coatings and other coatings well
known in the pharmaceutical formulating art. In such solid
dosage forms, the active compound may be admixed with at
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least one inert diluent such as Sucrose, lactose or starch. Such

dosage forms may also comprise, as is normal practice, addi
tional Substances other than inert diluents, e.g., tableting
lubricants and other tableting aids such a magnesium Stearate
and microcrystalline cellulose. In the case of capsules, tablets
and pills, the dosage forms may also comprise buffering
agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
Substances and waxes.
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agent.

The compounds of this invention or pharmaceutically
acceptable compositions thereof may also be incorporated
into compositions for coating an implantable medical device,
Such as prostheses, artificial valves, vascular grafts, stents and
catheters. Accordingly, the present invention, in another
aspect, includes a composition for coating an implantable
device comprising a compound of the present invention as
described generally above, and in classes and Subclasses
herein, and a carrier Suitable for coating said implantable
device. In still another aspect, the present invention includes
an implantable device coated with a composition comprising
a compound of the present invention as described generally
above, and in classes and Subclasses herein, and a carrier
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Dosage forms for topical or transdermal administration of
a compound of this invention include ointments, pastes,
creams, lotions, gels, powders, Solutions, sprays, inhalants or
patches. The active component is admixed under sterile con
ditions with a pharmaceutically acceptable carrier and any
needed preservatives or buffers as may be required. Oph
thalmic formulation, eardrops, and eye drops are also con
templated as being within the scope of this invention. Addi
tionally, the present invention contemplates the use of
transdermal patches, which have the added advantage of pro
viding controlled delivery of a compound to the body. Such
dosage forms are prepared by dissolving or dispensing the
compound in the proper medium. Absorption enhancers can
also be used to increase the flux of the compound across the
skin. The rate can be controlled by either providing a rate
controlling membrane or by dispersing the compound in a
polymer matrix or gel.
As described generally above, the compounds of the inven
tion are useful as treatments for HPV diseases, including
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chronic HPV diseases.
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More than one compound of the invention may be admin
istered separately, simultaneously, or sequentially to infected
cells, to tissue containing the infected cells, to infected organ
isms, including mammals and patients.
It will also be appreciated that the compounds and phar
maceutically acceptable compositions of the present inven
tion can be employed in combination therapies, that is, the
compounds and pharmaceutically acceptable compositions
can be administered concurrently with, prior to, or Subse
quent to, one or more other desired therapeutics or medical
procedures. The particular combination of therapies (thera
peutics or procedures) to employ in a combination regimen
will take into account compatibility of the desired therapeu
tics and/or procedures and the desired therapeutic effect to be
achieved. It will also be appreciated that the therapies
employed may achieve a desired effect for the same disorder
(for example, an inventive compound may be administered
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concurrently with another agent used to treat the same disor
der), or they may achieve different effects (e.g., control of any
adverse effects). As used herein, additional therapeutic agents
that are normally administered to treat or prevent a particular
disease, or condition, are known as “appropriate for the dis
ease, or condition, being treated'.
The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the
amount that would normally be administered in a composi
tion comprising that therapeutic agent as the only active
agent. Preferably the amount of additional therapeutic agent
in the presently disclosed compositions will range from about
50% to 100% of the amount normally present in a composi
tion comprising that agent as the only therapeutically active
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suitable for coating said implantable device. Suitable coat
ings and the general preparation of coated implantable
devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026;
and 5,304,121. The coatings are typically biocotnpatible
polymeric materials such as a hydrogel polymer, polymeth
yldisiloxane, polycaprolactone, polyethylene glycol, poly
lactic acid, ethylene vinyl acetate, and mixtures thereof. The
coatings may optionally be further covered by a Suitable
topcoat of fluorosilicone, polysaccarides, polyethylene gly
col, phospholipids or combinations thereof to impart con
trolled release characteristics in the composition.
VI. Methods of Treating
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Another aspect of the invention relates to treating HPV or
papilloma virus infected cells or other papilloma virus in a
biological sample or a patient (e.g., in vitro or in vivo), which
method comprises administering to the patient (human or
other animal), or contacting said biological sample with a
pharmaceutical composition comprising a polyamide as
described herein. The term “biological sample, as used
herein, includes, without limitation, cell cultures or extracts

thereof; biopsied material obtained from a mammal or
extracts thereof, and blood, saliva, urine, feces, semen, tears,
55
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or other body fluids or extracts thereof. The term “patient’
includes animals, including mammals, humans, primates,
dogs, cats, horses, pigs, cows, sheep and the like.
After the cells of an individual become exposed and
infected with an HPV, a number of HPV episome copies may
become established within an infected cell. The HPV epi
Somes further replicate as the cells divide, forming approxi
mately the same number of HPV episomal copies in each new
cell (e.g., upon cell division, a cell containing 20-100 copies
will form two new cells, each containing approximately
20-100 episome copies. Polyamides designed to target A/Trich regions can promote the clearance of HPV episomes.
Hence, the methods of the present invention can also be used
beneficially as a therapeutic method to treat HPV.
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The polyamides used to treat HPV or other papilloma
viruses include, without limitation, those described herein.
In one embodiment, the invention provides a method of
treating WV infected cells comprising contacting the cells
with a compound described herein. In an aspect of the inven
tion, the method further comprises contacting the cells with
an anti-viral agent. The antiviral agent can be an Interferon,
imiquimod, cidofovir, formaldehyde, glutaral, cimetidine,
5-fluorouracil, trichloroacetic acid, bleomycin, podofilox or
podophyllum.
In another embodiment, the invention provides a method of
treating HPV infected cells in a patient or Subject, comprising
administering to a patient or Subject a compound or pharma
ceutical composition described herein. In an aspect of the
invention, the method further comprises contacting the cells
with an anti-viral agent. The anti-viral agent can be an Inter
feron, imiquimod, cidofovir, formaldehyde, glutaral, cimeti
dine, 5-fluorouracil, trichloroacetic acid, bleomycin, podo
filox or podophyllum. In another aspect, the HPV can be HPV
11, HPV 16, HPV 18, HPV 1, HPV6 or HPV31.
In other embodiments, the invention provides a method of
treating HPV 16 infected cells comprising administering to a
patient a compound of the formula
or a pharmaceutically acceptable salt thereof, wherein: m+3
is at least 11; and the other substituents are as described
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above.

In yet other embodiments, the invention provides a method
of treating HPV 16 infected cells by administering to a patient
a compound selected from
ImPPBPIPBPPYPPBPPPBPPPBTa:
ImPPBPPPYPPBPPPPBTa:
ImPPPBPPByPPBPPPBPBTa:
ImPPPBPPBYPPBPPPBPBTa:
ImPPPBPPPyPPPBPPPBBTa;
ImPPBPPPyPPBPPPPBTa;
ImPPBPPPyPPBPPPPTa;
ImPPBPPPYPPBPPPPBTa:
ImPPPBPPByNH2PPBPPPBPBDp;
ImPPPBPPBPPPYPPPBPPPBPPPBDp;
ImPPBPPPyPPBPPPPBDp;
ImPPPBPPBPPPyPPPBBPPPBPPPBDp;
ImPPPBPPPPPPPPPP3RDp;
ImPPBPPPYPPBPPPPBDp;
ImPPPBPPPPPPPPPP3|Ta;
ImPPBPIPBPPYPPBPPPBPPPBDp;
ImPPBPPBPIYPBPPBPPPBPBDp; and
ImPPPBPPByPPBPPPBPBDp;
and pharmaceutically acceptable salts thereof.
In aspects of the embodiment, the method further com
prises administering an anti-viral agent. The antiviral agent
can be an Interferon, imiquimod, cidofovir, formaldehyde,
glutaral, cimetidine, 5-fluorouracil, trichloroacetic acid,
bleomycin, podofilox, podophyllum, acyclovir and other
Herpes/cytomegaloviral drugs, and anti-HIV drugs.
In some embodiments, the polyamides used to treat HPV
infected cells or to treat HPV in a subject have the structure
selected from the group of
ImPPPBPPPyPPPBPPPBBTa (NV 1031); and
ImPPPBPPBYPPBPPPBPBTa (NV 1032).
In other embodiments, the polyamides used to treat HPV
infected cells or to treat HPV in a subject have the structure
selected from the group of
ImPPPBPPYPPPBPPPBDp;
ImPPPBPPBPPPPPPBPPPBPPPBDp;
ImPPPBPPBPPPyPPPBPPPBPPPBDp;
ImPPBPPPYPPPBPPPBTa; (NV 1020, 4Ta)
ImPPPBPPByPPBPPPBPBDp;
ImPPBPPPyPPBPPPPBDp;
ImPPBPPPYPPBPPPPBDp;
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ImPPPBPPPYPPPBPPPBBDp;
ImPPPBPPByPPBPPPBPBTa;
ImPPBPPPyPPBPPPPBTa;
ImPPPBPPBYPPBPPPBPBDp;
ImPPBPPPYPPBPPPPBTa; (NV 1030)
ImPPPBPPPPPPPPPPPRTa; (NV 1033)
ImPPBPIPBPPYPPBPPPBPPPBTa:
dImPPBPPPYPPPBPPPTa
In other embodiments, the polyamides used to treat HPV
infected cells or to treat HPV in a subject are selected from
ImPPPI-y-PPPPP-B-Dp: Im-PPPBDp;
ImPPPPImPPPPI-y-PPPPPPPPPP-B-Dp; ImPPPPPIPP
PyPPPPPPPPPPBDp;
ImPPPPPPPIPPPP-y-PPPPPPPPPPPPP-B-Dp, ImPPPPP
PPPIPPPPPP-y-(P)-(BDp;
ImPPI(P)-y-(P)-B-Dp; and
Im-(P)o-Y-(P)-B-Dp.
In still other embodiments, the polyamide used to treat
HPV infected cells or to treat HPV in a subject is selected
from
ImPPPBPPPBIPPPBPP-y-PPPBPPPBPPPBPPPBDp;
Im(P)-(3-PPPI-B-PPPBP-y-PPPP-R-PPP-3-PPPPy?-P-3Dp:
Im-B-(P)-B-PP-I-P-B-PPP-B-y-P-B-(P)5-B-PPP-B-PPP
B-Dp; and
Im-P-3-(P)-B-P-Im-PP-E-PPP-y-B-PPP-B-(P)-B-PPP-3P-B-Dp.
In still other embodiments, the polyamide used to treat
HPV infected cells or to treat HPV in a subject is selected
from
ImPPPPPPPPIPPPPP-y-PPPPPPPPPPPPPP-R-Dp;
ImPPPPPPPPIPPPP-y-PPPPPPPPPPPPP-B-Dp;
ImPPPPPPPPIPPP-y-PPPPPPPPPPP-3-Dp; and
ImPPPPPPPPIPP-y-PPPPPPPPPPP-B-Dp.
In another embodiment, the polyamide used to treat HPV
infected cells or to treat HPV in a subject is selected from:
ImPPBPPIBPPyPPBPPPBPPPBDp;
ImPPBPPIBPPyPPBPPPBPPPBTa;
ImPPBPIPBPPIyBPBPPPBPPPBTa;
ImPPPBPPPBPPyPPPBPPPBPPPBDp;
ImPPPBPPPBPPyPPPBPPPBPPPBTa;
ImPPBPPIBPPYPPBPPPBPPPBTa:
ImPPBPPIBPPYPPBPPPBPPPBDp;
ImPPBPPIBPPYPPBPPPBPPPBDp;
ImPPBPPIBPPYPPBPPPBPPPBTa:
ImPPBPPIBPPYPPBPPPBPPPBDp;
ImPPBPPIBPPyPPBPPPBPPPPTa; or
ImPPBPPPyPPBPPPPPTa
or a pharmaceutically acceptable salt thereof;
wherein:

Im is desamino-imidazole;
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P is 4-amino-2-carbonyl-N-methylpyrrole;
B is B-alanine;
I is 4-amino-2-carbonyl-N-methylimidazole;
Y is Y-aminobutyric acid,
Y is (R)-2,4-diaminobutyric acid reacted through either
the 2-amino group or the 4-amino group;
Y
is (R)-2-(acetylamino)-4-aminobutyric acid;
Ta is 3,3'-diamino-N-methyldipropylamine; and
Dp is dimethylaminopropylamine.
In still yet other embodiments, the polyamides used in
combination with otherantivirals, such as, without limitation,
Interferons, (e.g., Interferon-y and Interferon-3), imiquimod,
cidofovir, formaldehyde, glutaral, cimetidine, 5-fluorouracil,
trichloroacetic acid, bleomycin, podofilox, podophyllum,
acyclovir and other Herpes/Cytomegalovirus treatments, and
anti-HIV drugs. The polyamides can also be used in combi
nation with photodynamic therapy, radiation therapy and che
motherapy.
In order that the invention described herein may be more
fully understood, the following examples are set forth. It
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TABLE 3-continued

Mass Spectral Data of Polyanides with compound numbers and formulae.
i

Compound

1049 ImPPBPPIPPPPPBPPPBPPPBTa *
1050 ImPPBPPIPPPYPPBPPPBPPPBDp *

1056 ImPPPBPPpyPPBPPPBPPDp *
1066 ImPPBPPIPPPYPPBPPPBPPPBDp *
1067 ImPPBPPIPPPPPBPPPBPPPBTa *

1068 ImPPBPPIPPPYPPBPPPBPPPBDp *
1069 ImPPBPPPyPPBPPPPPTa

1070 ImPPBPPIBPPyPPBPPPBPPPPTa:

Theoretical MS

Experimental MS

(M + 2H) = 1271.1
(M+3H)" = 847.7
(M + 2H) = 1249.6
(M + 3 H) = 833.4
(M + 2H) = 1023.0
(M + 2H) = 1249.6
(M + 3 H) = 833.4
(M + 2H) = 1271.1
(M + 4H) = 636.0
(M + 2H) = 1270.6
(M + 3 H) = 847.4
HRMS (M + H) =

(M + 2H) = 1271.5
(M + 3H) = 848.0
(M + 2H) = 1250.0
(M + 3H) = 833.8
(M + 2H) = 1023.3
(M + 2H) = 1250.0
(M + 3H) = 833.8
(M + 2H) = 1271.5
(M + 4H) = 636.3
(M + 2H) = 1271.0
(M + 3H) = 847.8
HRMS (M + H) =

1944.8933

1944.8774

(M + 2H) = 1289.1
(M+3H)* = 859.7

(M + 2H) = 1289.5
(M + 3H) = 860.0

* MW was determined by standard resolution LCMS-ESI or direct probe ESI.
** MW was determined by MALDI,
HRMS = High Resolution Mass Spectrometry (done by ESI on an ion trap (MS), always preceded by standard resolution ESI).

(M+H+H): Mass spectroscopy conditions sometimes
cause apparent gas-phase hydrogenation of polyamides to
occur, leading to a MW of M+2. This phenomenon has been
previously observed by James K. Bashkin with other het
eroaromatic polyamide molecules. NMR studies of bulk
material previously showed that no hydrogenated species was
present in dissolved samples of the compounds. Newer mass
spectrometry results with gentler ionization techniques (i.e.,
ESI instead of MALDI and/or newer ESI conditions) have,
for those compounds re-examined, eliminated apparent gas
phase reductions and the ions based on protonation of neutral,
reduced M--2H species.
Polyamide 1011 was previously described in PCT Int.
Appl. WO04/099131; polyamides 1012, 1014, 1017 and
1021 have been described in PCT Int. Appl. WO98/37067:
polyamides 1005, 1006, 1007, 1008 and 1020 were described
in PCT Int. Appl. WO05/033282. In polyamides 1049 and
1050, the 2-amino group of the (R)-2,4-diaminobutyric acid
was reacted into the backbone of the compound to provide an
alpha turn. In all other compounds containing a Y building
block, the 4-amino group of the (R)-2,4-diaminobutyric acid
was reacted into the backbone of the compound to provide a
gamma turn.

The polyamides were tested in cells that maintain HPV 16
DNA and compared with other antiviral treatments. Several
antiviral treatments are available for treating HPV-induced
lesions. Cidofovir is an acyclic nucleoside phosphonate that
has shown some effectiveness against recurrent respiratory
papillomatosis (RRP), a rare disease of the airways caused by
HPV infection (Snoeck et al., 1998, J. Med. Virol. 54(3:
219-225). Cidofovir is used in the clinic by direct injection
into laryngeal lesions. Cidofovir and interferon are the two
primary options for treatment of this serious disease. Com
parisons of the antiviral activity of cidofovir and interferon Y
with polyamides that have antiviral activity toward HPV 16
indicate that the ICso of the polyamides tested is at least /1000
lower than the ICs of Cidofovir and interferony (IFNY (FIG.
1)).
Cells maintaining HPV 16 DNA were cultured for 72 hours
in the presence of cidofovir, interferon Y or polyamide. Viral
DNA was then quantified using real-time PCR and compared
to vehicle (DMSO)-treated control cultures. As shown FIG.1.
cidofovir resulted in a loss of approximately 40% of the total
HPV DNA content (but only at very high concentrations).
(The ICs is the concentration of compound required for 50%
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inhibition of viral replication in vitro.) These results agree
favorably with a previous study of cidofovir effects on HPV
episomal DNA (Spanos et al., 2005, Ann Oto. Rhino. Laryn
gol. 114(11): 840-846).
In contrast, the polyamides caused a much more significant
loss of viral episomal DNA content at significantly lower
concentrations. (See FIG. 1 and Table 4.) Indeed, NV 1028
was shown to reduce HPV episomes to undetectable levels by
QPCR when cells were exposed to concentrations as low as 5
uM. (200 ug of DNA was the input amount for the PCR
reaction.) NV 1028 has an ICs of 0.1 uM against HPV 16.
These results demonstrate that the compounds of the inven
tion possess considerably Superior potency in cell culture to a
drug that is currently being used in the clinic for treatment of
HPV-caused lesions. In these assays, polyamides exhibited
increases in potency relative to interferon, which is also cyto
toxic. Results are shown in FIG. 1 for interferony, and similar
results were obtained with interferon B.
Compounds were initially tested for effects on HPV 16
episome DNA levels in W12E cells by Q-PCR (TaqmanTM)
over 3 concentration ranges (0.1, 1 and 10 uM). W 12E cells
area cervical keratinocyte cell line originally identified by M.
Stanley (Cambridge University), and later optimized and pro
vided by P. Lambert (U. of Wisconsin). Those compounds
showing evidence of dose-dependent inhibition at these con
centrations were next tested using a minimum of 6 doses over
a range of concentrations from 1.0 uM to 10 uM so that ICso
values could be obtained. In all cases (initial tests and follow
up ICso tests), dose testing was performed in triplicate. For
each compound, the log dose-response was plotted and a
best-fit curve generated by Microsoft Excel, Xlfit (version
2.0; ID Business Solutions, Guildford, UK), which allows
curve fitting using nonlinear regression. Data were plotted as
percent inhibition vs. dose, and the ICso was defined as the
drug concentration required for a 50% reduction in HPV
DNA relative to vehicle-treated (0.1% DMSO) controls. Fur
thermore, all experiments were conducted in triplicate, mul
tiple times. The data were then combined, pseudo or effective
ICso values calculated, and variance determined to reveal the
fit of the data to the model and its reliability. The data for one
of the most potent polyamides, 1028, is shown in FIG. 2. All
experiments on active compounds were conducted this way.
A dose-dependent decrease in HPV 16 DNA copy number
after polyamide treatment (n=4 independent experiments) is
shown in FIG. 2B. No accompanying effect on cell viability
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(MTT assay) was observed. Cells were cultured for 5 days in
the presence of polyamide: % Cell Viability=(OD590 drug/
OD590 control)x100; n=3.
Table 4 presents a Summary of exemplary and inactive
polyamides and pseudo (or effective) ICso values against
HPV 16, HPV 18 and HPV31. In Compounds 1049 and 1050,
the unit designated “Y” is (R)-diaminobutyric acid which
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has been incorporated into the polyamide Such that the alpha
amino group has been reacted to become part of the polymer
backbone (e.g., Y, in these compounds corresponds to the
structure - NH-CH(CHCH-NH)–C(=O) ). Potential
targets in the HPV genome are indicated for those compounds
targeting SEQ. ID. NO. 1 or SEQ. ID NO.2.
TABLE 4

Effective ICso Values of Polyamides Against HPV 16, 18 and 31
HPV 16 HPV-16 HPV18.

HPV31

target # ICso

ICso

ICso

028. ImPPBPPPyPPBPPPPPTa
030 ImPPBPPPYPPBPPPPBTa

1, 4
1, 4

-------

-------

-------

029
037
004
027

4
3
4
4

-------------

---------------

---------------

003 ImPPPBPPBPPPYPPPBPPPBPPPBDp
032 ImPPPBPPBYPPBPPPBPBTa

4
4

---NA

031 ImPPPBPPPYPPPBPPPBBTa
026 ImPPPBPPPYPPPBPPPBBDp

4
4

-------------

-------------

i

Compound

ImPPPBPPBYPPBPPPBPBDp
ImPPBPIPBPPYPPBPPPBPPPBTa
ImPPPBPPBPPPyPPPBPPPBPPPBDp
ImPPPBPPBYPPBPPPBPBTa

---NA

020 ImPPBPPPYPPPBPPPBTa (4Ta)

1, 4

--

NT

----

033 ImPPPBPPPYPPPBPPPBBTa
024 ImPPBPPPYPPBPPPPBDp

4
1, 4

---

NA
--

-----

023 ImPPBPPPYPPBPPPPBDp

1, 4

--

NT

--

022 ImPPPBPPBYPPBPPPBPBDp

4

--

NT

--

002 ImPPPBPPYPPPBPPPBDp
005 ImPPPPYPPPPPBTa (1Ta)
006 ImPPPPPPPPPBTa (3Ta)

1, 4
1, 4
1, 4

NA
NA
NA

NA
NA
NA

NA
NA
NA

1007 ImPPPPPPPPPBTa-FITC (1 Ta)

1, 4

NA

NA

NA

008 ImPPPPYPPPPPBTa-BOFLX (1Ta)
010 ImPPPPYPPPPPBDp (1 Da)

1, 4
1, 4

NA
NA

NT
NA

NA
NA

011
012
013
014
015
016
017
018.
019
021
025
O38
O39

2

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

NA
NA
NT
NT
NT
NT
NT
NT
NT
NA
NT
NA
NA

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

04.0 ImPPBPPIPPPYPPBPPPBPPPBDp

----

----

----

041 ImPPBPIPBPPIYBPBPPPBPPPBDp

NA

NA

NA

042
045
O47
048.
049
050

-----------------

-----------------

---------------

ImPPIYPPPPBDp
ImIIPYIPPPBDp
ImPPPYPPIPBDp
ImpIPYIPPPBDp
ImpIPYPPPPBDp
ImpIIPYPPPPPBDp
ImPPIyPIIPBDp
ImpIPPYIPPIPBDp
ImPPIPYIPIPPBDp
ImIPIyPIPPBDp
ImPPPBPPPYPPPBPPPBBDp
OHC-PPPPBDp
OHC-PPPPPPBDp

ImPPBPPIPPPYPPBPPPBPPPBTa
ImPPBPIPBPPIYBPBPPPBPPPBTa
ImPPPBPPPBPPyPPPBPPPBPPPBDp
ImPPPBPPPBPPyPPPBPPPBPPPBTa
ImPPBPPIPPPYPPBPPPBPPPBTa
ImPPBPPIPPPYPPBPPPBPPPBDp

O56 ImPPPBPPBYPPBPPPBPPDp
066
067
068
O69
070

ImPPBPPIPPPYPPBPPPBPPPBDp
ImPPBPPIPPPYPPBPPPBPPPBTa
ImPPBPPIPPPYPPBPPPBPPPBDp
ImPPBPPPyPPBPPPPPTa
ImPPBPPIBPPyPPBPPPBPPPPTa

4

4
4

4

4

NA

NA

NA

----------------

--------------

----------------

+++ indicates an IC50 of 0.1 uMorless;
++ indicates an IC50 of between 0.1 and 1.0 uM;
+ indicates an IC50 of 1.0 Morgreater;
NA indicates no measurable antiviral response was obtained relative to control at the highest dose tested;
NT indicates Not Tested.
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Surprisingly, NV 1020 was effective against HPV 16, with
an ICs between 0.1 and 1.0 uM.
Shorter polyamides and less-traditional polyamide struc
tures (Laemmli and Janssen, 2002a: Laemmli and Janssen,
2002b: Maeshima et al., EMBO J., 20, 3218-28, 2001) were
inactive in this study. Among the inactive compounds was
3-Ta, ImPPPPYPPPPPBTa, which contains the 2,4-di
amino-hairpin: Y. Compound 3-Ta recognizes similar
DNA targets as 2-Ta (which has the structure ImPPBPPPYP
PPBPPPBTa) and 4-Ta, except that 3-Tabinds to only 8 base
pairs, while 2-Ta and 4-Tabind 10 base pairs.
Example 2
Polyamide Toxicity Testing: TC50 is not Reached at
300 uM
Toxicity testing has been carried out for 3 separate polya
mides. Two different Rathepatoma assays were used because
they are industry standards for predicting in vivo toxicity. The
assays for ATP and membrane integrity assays are described
in detail below. Thus, rathepatoma cells (H4IIE) were seeded
into 96-well plates and cultured in medium containing 20%
bovine serum. Following an equilibration period of 48 hr, the
cells were treated with the test compounds at various concen
trations for 24hr at 37°C. in 5% CO. Polyamide compounds
were tested for toxicity in the two separate assays. A TCso
(concentration needed to kill half of the cells) was not
achieved for any polyamides tested over the wide concentra
tion range explored. (The TCs for NV1028 was estimated to
be greater than 300 uM.) On the other hand, control com
pounds rotenone and camptothecin (data not shown) pro
ducedTCs values of 0.49 uM (rotenone) and 5.0 uM (camp
tothecin) in the membrane integrity assay, and 0.05
(rotenone) and 0.9 (camptothecin) in the ATPassay. In addi
tion, Cidofovir produced a TCs of 750LM in the MTT assay.
A brief description of the assays follows.
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30-40 mm. During method development experiments, it was
determined that Triton-X-100 was the best solution to perme
abilize the H4IIE cells thereby allowing the PI access to
intracellular RNA and DNA. Fluorescence was measured

using a Packard Fusion plate reader at 540 mm excitation and
610 nm emission.

10

15

25

30

35

40

45

50

cell.

At the end of the 24-hr exposure period the medium was
removed from the cells and the ATP cell lysis buffer added to
each well. Plates were analyzed immediately or stored at 20°
C. until needed. On the day of analysis, the plates were
thawed and calibration curve prepared with ATP in the same
liquid matrix as samples. ATP was quantified by adding ATP
Substrate solution and then reading luminescence on a Pack
ard Fusion Luminescence or equivalent plate reader.
B. Membrane Integrity/Modified Propidium Iodide Proce
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A modified propidium iodide (PI) procedure was used to
assess cell proliferation/viability. This specific nucleic acid
binding dye fluoresces when intercalated within the nucleic
acids. The 151 lm shift enhances PI fluorescence approxi
mately 20 times while the excitation maxima are shifted

Example 3

Testing Polyamides

A. Intracellular ATP Levels

Cellular Adenosine triphosphate (ATP) levels were deter
mined using an assay based on a reaction between ATP+Dluciferin-i-oxygen catalyzed by luciferase to yield Oxylu
ciferin-AMP+PPi+CO2+light. The emitted light is
proportional to the amount of ATP present. Rather than a
“flash' type signal, which has a very short half-life, this assay
utilizes a proprietary "glow technology that extends the sig
nal half-life to 5 hr. In addition, a unique cell lysis reagent
inhibits endogenous ATPases and therefore stabilizes cellular
ATP by preventing its degradation to ADP ATP is present in
all-living cells and declines rapidly upon cell death. In addi
tion, this assay in combination with the MTT assay provides
an indicator of mitochondrial activity and energy status of the

C. MTT Assay
The MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet
razolium bromide assay, first described by Mosmann in
1983, is based on the ability of a mitochondrial dehydroge
nase enzyme from viable cells to cleave the tetrazolium rings
of the pale yellow MTT and form dark blue formazan crystals
which are largely impermeable to cell membranes, thus
resulting in its accumulation within healthy cells. Solubilisa
tion of the cells by the addition of a detergent results in the
liberation of the crystals which are solubilized. The number
of surviving cells is directly proportional to the level of the
formazan product created. The color can then be quantified
using a simple colorimetric assay. The results can be read on
a multiwell scanning spectrophotometer (ELISA reader).
(Mosmann T. Rapid colorimetric assay for cellular growth
and Survival: application to proliferation and cytotoxicity
assays, JImmunol Methods, 65, 55-63, 1983).
HPV viral DNA is quantified in cultured W 12E cells as
previously described using Taqman primers and probes
(Peggy Garner-Hamrick and Fisher, C, HPV Episomal Copy
Number Closely Correlates with Cell Size in Keratinocyte
Monolayers, Virology 2002: 301: 334-341.)
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Polyamides have been reproducibly shown to obey the
rules of DNA binding that have been developed largely by
Dickerson and Dervan. The polyamides of this invention
possess high binding constants between polyamides and their
matched DNA sequences. In these experiments, the DNA
target was immobilized to a BIA core chip by biotin-Avidin
affinity, and both kinetics and thermodynamics of polyamides
binding were examined.
Cell Culture Assays
A highly quantitative real-time PCR assay (Garner-Ham
rick and Fisher, Virology, 301, 334-41, 2002) was used to
measure HPV 16 episomal DNA levels following treatment
of cells with polyamides. Keratinocytes that maintain HPV
16 episomes were treated with increasing concentrations of
polyamides. Shown in FIG. 3 are five polyamides, which
exhibit dose dependent effects on absolute HPV 16 DNA
levels. Remarkably, the higher doses of 1031, 1037, 1028 and
1004 resulted in nearly complete elimination of detectable
viral DNA in some experiments (FIG. 3).
The anti-HPV 16 results are not likely to be caused by
cellular toxicity for a number of reasons, one being that
throughout all experiments, the cells were morphologically
normal and continued to proliferate normally as determined
by cell counting and density. Cell viability was also assessed
routinely with the MTT assay. The assay employed in the
experiments in FIG. 3 utilized TaqmanTM PCR amplification
of the HPV 16 L1 gene (Garner-Hamrick and Fisher, Virol
ogy, 301,334-41, 2002).
Several alternative approaches have been used to confirm
the effects of our compounds on viral DNA. These additional
procedures include normalization to total DNA, preparation
of DNA by different procedures including DNeasy (Total
Genomic DNA) Qiagen spin columns, DNAZol total genomic
DNA preparations, and Hirt (low MW DNA preparations:
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(Hirt, (1967), J Mol Biol. 26:365-9). In all cases, our results
have been entirely consistent with reduction of episomal
DNA content in cells by our compounds. Finally, Southern
blotting confirmed that decreases in viral DNA, measured
using Q-PCR, are consistent with more traditional, although
less quantitative, procedures. FIG. 4 shows a Southern blot
showing dose-dependent elimination of HPV episomal DNA
from a human keratinocyte cell line harboring HPV DNA
exposed in culture to a polyamide. DMSO is the vehicle
control; HPV DNA indicates the linearized HPV DNA used

to generate the hybridization probe via random primed label
ing with DIG-dUTP (Roche); following hybridization, blot
was incubated with anti-DIG-AP conjugate and HPV DNA
detected using ECF substrate (Amersham) and Storm phos
phorimager. NV 1020 (indicated by the lanes marked 1 uM
and 10 uM), with an approximate ICso of 1.3 uM, gave the
expected decrease in episomal DNA content. Other NV com
pounds have similarly shown the expected decrease in viral
DNA by Southern blotting.
Polyamides were also found to be more potent than the
naturally occurring polyamides, netropsin and distamycin,
and, unlike metropsin and distamycin, had little effect on cell
viability (FIG. 5). FIG. 5 compares the relative effects of
1037, distamycin A and cidofoviron HPV viral DNA and cell
viability. Polyamide 1037 shows dramatic reduction of viral
DNA levels at concentrations that have little impact on cell
viability. Cidofovir and distamycin A are only effective
against HPV DNA at high concentrations that also affect cell
viability.
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pamil, an agent that disrupts acidic vesicle homeostasis,
blocked vesicular accumulation and led to nuclear accumu

10

the nucleus of the cell.

15

Since nuclear DNA is a proposed polyamide target, polya
mides may indeed be useful compounds for regulating gene
expression in mammalian cells when, e.g., one of the two
strategies outlined here is used to deliver polyamides to the
nucleus (Crowley et al., Bioorg. Med. Chem. Lett., 13, 1565
70, 2003). (See Best et al., Proc. Natl. Acad. Sci. USA, 100,
12063-68, 2003: Edelson et al., Nucl. Acids Res., 32: 2802

18, 2004). Keratinocytes of the type used herein (i.e. W12E
cells) have not required special nuclear targeting strategies to
be used in cell or tissue culture experiments for effective
antiviral polyamide design.
Example 6

25

Identification of Polyamides for HPV 18
30

Example 4
Effect of Withdrawal of Polyamide on HPV 16
Episomes
35

This experiment was performed to determine whether the
decrease in HPV 16 episomes is maintained after a polyamide
is withdrawn from cells. Cells were plated on day 1 of experi
ment and 10 uM NV 1028 added; cells were cultured for 3
days at which time cells were washed and fresh 1028 added:
sub-culturing in the presence of 1028 was performed at the
indicated days (X-axis) for 15 days; drug was washed out on
day 17 and cells were sub-cultured in the absence of drug for
2 weeks to check for HPV 16 episomal DNA rebound. Con
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trol W12E cells received 0.1% DMSO. FIG. 7 shows that
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HPV episomal DNA rebounds somewhat when a polyamide
is withdrawn, but recovery does not approach control levels
for at least two weeks after polyamide withdrawal.
Example 5
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Control of Cellular Uptake and Nuclear Localization
for Polyamides
As described above, polyamides of this invention readily
localize to the nucleus of keratinocytes. However, in other cell
types, including various transformed cells, polyamides often
localize within Vesicular compartments following treatment
of cells. Polyamide uptake and cellular distribution were
obtained by studying the effects of overall polyamide charge
and acidity, and the influence of multi-drug resistance inhibi
tors on uptake (Crowley et al., Bioorg. Med. Chem. Lett., 13,
1565-70, 2003).
The studies revealed that BODIPY-labeled polyamides
accumulate in acidic vesicles, mainly lysosomes, in the cyto
plasm of mammalian cells. This is a phenomenon observed
with many drugs and compounds that are mild bases. Vera

lation of the BODIPY-labeled polyamide. These results sug
gest that the basic amine group commonly found at the end of
synthetic polyamide chains is responsible for their accumu
lation in cytoplasmic vesicles in mammalian cells. In Support
of this suggestion, we found that modifying the charge on a
polyamide by replacing the BODIPY moiety on the amine tail
with a fluorescein moiety generated a new molecule that did
not accumulate in cytoplasmic vesicles but rather localized to

DNA-binding polyamides of this invention are directed
against HPV 16 that potently and dramatically decrease virus
episomal DNA levels in human keratinocytes. Here we
describe approaches to finding antiviral agents for HPV 18. In
one approach, the manner in which HPV is tethered to the
host chromosomes will be used to target HPVs.
Polyamides are prepared by literature methods (e.g. Bel
itsky et al., Bioorg. Med. Chem., 10, 2767-74, 2002), and the
method described in Example 8 below, using building blocks
synthesized in-house. These include solid phase, such as Mer
rifield synthesis, and solution methods. All final products will
be purified by HPLC to >98% purity, then aliquotted, lyo
philized and stored frozen untiluse. The ability of polyamides
to bind their nominal DNA targets, will be assessed by BIA
core analysis. Sufficient quantities are prepared for prelimi
nary toxicity.
The design of polyamides to target A/T-rich regions of
HPV 18 is based on the five known recognition rules. Pyrrole
recognizes A, T, or C, B-alanine, Y-turn and amino tail all
recognize nucleotides A or Tand sometimes C, and imidazole
recognizes G. Three important aspects of the polyamides
effective against HPV include: (1) polyamide sequences that
result in clearance of HPV 18; (2) Discovery of polyamide
lengths that balance efficacy and uptake; (3) Discovery of
where 3-alanine groups are best incorporated in the polya
mide.
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TABLE 5

Polyamides for HPV 18.
60

1
2
3
4
5
6
7

ImPPI-y-PPPPP-p-Dp
ImPPPPIPPPPI-y-PPPPPPPPPP-B-Dp
ImPPPPPIPPP-y-PPPPPPPPPP-B-Dp
ImPPPPPPPIPPPP-y-PPPPPPPPPPPPP-B-Dp
ImPPPPPPPPIPPPPPP-y-PPPPPPPPPPPPPPP-p-Dp
Im-P-I(P)o-Y-(P)-f-Dp
Im-(P)o-Y-(P)-f-Dp

8 base pairs
13 base pairs
13 base pairs
16 base pairs
17 base pairs
17 base pairs
14 base pairs
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All of the polyamides shown in Table 5, with the exception
of compound 1, are quite long. Versions of each polyamide
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are prepared with beta-alanines (B) incorporated to relieve
strain in the polyamide backbone due to slight imperfections
that show up in the fit to DNA with these lengthy molecules.
There are no set rules about where 3-alanines should be
placed, except that they interact unfavorably with G. A rep
resentative set of example variations in polyamide composi
tion is given in Table 6, with one added B on either side of the

5

Y-turn.
TABLE 6

10

Polyamide sequences based on one
compound modified with 3-alanine.
15

In addition, truncated versions of the polyamides are pre
pared and tested. This may improve uptake and will help
determine parameters for predicting length vs. selectivity.
Examples of truncated polyamides based on polyamide 5, one
of the two longest polyamides in Table 5, are given in Table 7.
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at 50° C. for 2 h. Lysates are then extracted with phenol/
chloroform/isoamyl alcohol and spun through a phase lock
gel (Eppendorf, Hamburg, Germany). Total DNA is then pre
cipitated with 0.3 MNaOAc and 2.5 vol. ethanol and resus
pended in Tris-EDTA (TE) buffer.
Viral DNA levels are next quantified according to varia
tions on our previously published methods (Garner-Hamrick
and Fisher, Virology,301,334-41, 2002). Quantitative PCR is
performed using Real-Time PCR technology on an ABI
PRISM 7700 Sequence Detector. All primers and probes were
designed using Primer Express 1.0 (ABI). For HPV 18, PCR
primer-probe sets were designed within the L1 gene: sense
5'-TTTGGTTCAGGCTGGATTGC (SEQ. ID, NO. 3), anti
sense 5'-GCAGATGGAGCAGAACGTTTG (SEQ. ID, NO.
4), probe 5'-TCGCAAGCCCACCATAGGCCC (SEQ. ID.
NO. 5). HPV31 primers-probe sets for PCR were also
designed within the L1 gene: sense 5'-CTGCTATTTTG
GAAGATTGGAAT (SEQ. ID. NO. 6), antisense 5'-GGCCT
GTGAGGTGACAAACC (SEQ. ID, NO. 7), probe 5'-TTG
GATTGACCACACCTCCCTCAGGTT (SEQ. ID, NO. 8).
All primers and probes are synthesized and HPLC purified
by Applied Biosystems (Foster City, Calif.). The HPV probes

TABLE 7

Truncated Polyamides recognizing one less base pair (bp) per entry
Shotter analogs of “parent polyamide

ImPPPPPPPPIPPPPP-y-PPPPPPPPPPPPPP-p-Dp
ImPPPPPPPPIPPPP-y-PPPPPPPPPPPPP-p-Dp
ImPPPPPPPPIPPP-y-PPPPPPPPPPP-p-Dp
ImPPPPPPPPIPP-y-PPPPPPPPPPP-B-Dp

One base pair shorter
Two base pairs shorter
Three base pairs shorter
Four base pairs shorter

The polyamide compounds of the invention are also useful
as tools to probe the HPV life cycle.
Human keratinocytes, including those maintaining HPV
episomes, are cultured on mitomycin C-treated J23T3 cells in
media containing three parts Dulbecco's modified Eagle
medium (DMEM) and one part F12 media, our modification
of published methods (Rheinwald and Green, 1975). Media
(E Media) is supplemented with 0.4 ug/mL hydrocortisone,
10 ng/mL cholera toxin, 5ug/mL insulin, 24 g/mL adenine,
5ug/mL transferrin, 5 Jug/mL 3.3',5-triiodo-thyronine (T),
10 ng/mL epidermal growth factor (EGF), 1% penicillin
streptomycin, and 5% fetal bovine serum (FBS). All cells are
passaged at 70% confluency at a split ratio of 1:5. Polyamides

35

range of 10 to 10 copies/reaction of cloned, genomic HPV31
or HPV 18 DNA using the following formula: (1.82x10')

(ug/LL stock DNA)/(length in base pairs)(2)-copies/ull Stock

40

DNA. PCR reactions contain final concentrations of 1x Uni
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versal Master Mix (PE Applied Biosystems), 200 nM of each
primer, and 250 nM probe (PE Applied Biosystems) in a
reaction volume of 25 uL. Each Hirt-isolated DNA sample is
analyzed in triplicate reactions for episomal HPV. Copies/
reaction are determined from the standard curve, and copies/
cell determined according to the following formula: (copies/
reaction)x(DNA dilution)/(total it cells)=copies/cell.
Example 7

for HPV 18 are dissolved at 10 mM in 100% DMSO and

diluted with HO to 1 mM. Polyamides are added to cells in E
media at final concentrations of 0.1-10 uM, with final DMSO
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concentrations of 0.1%. As controls, cells are incubated with

normal E media and E media containing the “vehicle' 0.1%
DMSO. The HPV DNA levels are then quantified according
to previously published procedures (Garner-Hamrick and
Fisher, Virology, 301, 334-41, 2002). After incubation, cells
are harvested from the plates by either trypsinization or direct
lysis with proteinase K digestion buffer (PK buffer: 100 mM
NaCl, 10 mM Tris pH 8, 25 mM EDTA, 0.5% SDS, 0.1
mg/mL proteinase K). Trypsinized cells are counted on a
hemocytometer and pelleted by centrifugation. Episomal
HPV is isolated by the Hirt method (Hirt, 1967) and cell
pellets are lysed in 0.6% SDS with 10 mM EDTA. NaCl is
next added to a final concentration of 1 M. Following an
overnight incubation at 4° C., precipitates containing the
chromosomal DNA are spun down and episomal DNA pre
cipitated by the addition of isopropanol. Cells lysed directly
in PK buffer are transferred to microfuge tubes and incubated

are labeled with the 5' reporter dye FAM (6-carboxyfluores
cein) and the 3' quencher dye TAMRA (6-carboxytetram
ethyl-rhodamine). A standard curve is generated using a

Initial In Vitro Toxicity Assessments
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Polyamides that significantly reduce HPV 18 DNA levels
can be further tested in a series of follow up studies. The
follow up studies will require re-preparation of the polya
mides on a larger scale.
Southern blotting is used to confirm the effects of polya
mides on HPV 18 DNA levels that were determined using
real-time PCR technology. The experiments are conducted as
previously described (Garner-Hamrick and Fisher, Virology,
301,334-41, 2002). Briefly, 5ug of total cell DNA from both
polyamide-treated and control cells is digested with BamHI
and run on a 0.7% agarose gel. After transfer to Nytran
(Schleicher & Scheull, Keene, N.H.), the DNA is probed with
gel purified full-length HPV 18 that has been liberated from
pUC19 with BamHI, and randomly primed in the presence of
DIG-UTP (Roche). Following incubation with anti-DIGAP
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(alkaline phosphatase), HPV DNA is detected with ECF sub
strate and phosphor-imaging. The experiments should con
firm the TaqmanTM assay results, and they provide an inde
pendent, orthogonal assay of activity.
Secondly, 50% and 90% effective concentration values
(EC50 & ECoo) are determined for each polyamide over a
dose range of 10 nM to 50 uM (10 nM, 100 nM, 500 nM, 1
uM, 5uM, 10uM, and 50 uM) using Taqman data. Previous
studies of ours indicate that this range should provide suitable
dose-response curves. The final levels of HPV DNA per cell
are determined for each polyamide concentration, and data is
expressed as % inhibition relative to vehicle-treated controls.
ECsos are then calculated using nonlinear regression analysis
with Sigmaplot software.
The toxicity of each polyamide found active against HPV
18 is monitored in normal human keratinocytes using an MTT
cell viability assay (Denizot and Lang, 1986). Polyamides are
initially supplied to normal keratinocytes in growth media at
concentrations of 10 nM, 100 nM, 1 uM, 10uM, 100 uM,500
uM, 1 mM and 10 mM. Each set of samples is supplied in
triplicate, in clear 96-well plates. A tetrazolium dye (3-4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide or
MTT. Sigma) is added to the cell cultures 48 hours after
addition of polyamides. After 4 hours cells are rinsed 1x with
PBS, and isopropanol containing 0.04N HCl is added to lyse
cells and solubilize MTT formazan. Plates are read on a plate
reader at a test wavelength of 570 mm and a reference wave
length of 630 nm. Data are expressed as % inhibition of
vehicle-treated controls and, as for analysis of effects on HPV
DNA levels, ICsos are calculated using nonlinear regression
analysis with Sigmaplot software.
The selectivity index for each effective polyamide is then
determined as the ratio of the ECs to the ICs (SIECso/
ICs). An SI of 5 is considered an acceptable starting point.
Finally, the effects of multiple dosing with polyamides are
followed in vitro. The purpose of these studies is to gauge the
extent to which polyamides can clear cells of episomal DNA
in the absence of an immune system. While it is recognized
that, in general, an intact immune system is important for
optimal antiviral effects, these studies are important to help
prioritize and select compounds designed to clear viral DNA
in animal studies. Since typical clinical antiviral regimens last
from 1 to 2 weeks or longer, we can dose HPV 18-positive
keratinocytes for 6, 9, and 12 days by providing fresh polya
mide with each change of medium. The HPV-18 kerati
nocytes are passaged during the course of these experiments
as needed. Dosage can be at levels >EC value as long as
those concentrations previously showed no significant toxic
ity. Treated cells are then collected for Taqman analysis and
also re-plated in fresh media. The re-plated cells are allowed
to recover for an additional 7 days at which time they are
harvested and viral DNA content analyzed by Taqman. The
viral DNA content of the recovered cells is then compared
with that of the cells at the end of the treatment regiment.
The data for HPV show a remarkable and potent reduction
in viral DNA levels. However, it is important to note that the
recovery or “rebound of viral DNA occurs after a single 48
hr. treatment. Polyamides were removed from culture at 48
hrs, but the HPV DNA levels and subsequent “rebound”
occurred many days later. Therefore, if all of the original
polyamide dose were still present in the cells at day 6, it would
have been diluted by a factor of at least four due to cell
doubling. Since most antiviral regimens last at least 7 to 14
days (and may last for months), we anticipate that the longer,
multiple dosing approach described here will reduce the abil
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ity of HPV to recover in vitro following treatment, and we
anticipate that Some polyamides may result in clearance of
HPV DNA.

Example 8
Methods for Preparation of
Poly-N-methylimidazole-N-methylpyrrole
Polyamides and Analogs that Lack a B-Alanine
Between the C-Terminal Heterocycle and the
C-Terminal Cationic End Group

10

15
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One method of synthesis is to prepare a polyamide oligo
mer starting with Boc-B-alanine-WANG solid phase synthe
sis resin, adding building blocks as required for the target
sequence. Preparing free carboxylic acids at the C-terminus
of polyamides allows polyamide molecules to be further
elaborated by Solution-phase coupling into a variety of struc
tures, including molecules that lack beta-alanine immediately
adjacent to a C-terminal polar group Such as the cationic
group(s) derived from aliphatic di- and triamines. Wang res
ins, especially in the form Fmoc-B-alanine-Wang, are useful
for this chemistry. These resins include, for example, the
trifluoroacetic acid-cleavable NovabiochemR) materials

known as NovaSyn R. TG HMP, NovaPeg Wang, HMPA
PEGA and HMPA NovaGelTM resins.

30
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The polyamide is cleaved from the resin with trifluoroace
tic acid. After cleaving a polyamide from its Wang or Wang
like resin by trifluoroacetic acid, trifluoroacetate is removed
from the product prior to coupling the C-terminal carboxylate
and a new amine to generate a C-terminal amide. In general,
lyophilization and/or ion exchange may be used to remove
trifluoroacetic acid or its anion prior to an amide coupling
reaction to elaborate the polyamide. Additionally, ion
exchange to make the hydrochloride (or similar) salt of a
cationic polyamide is preferred prior to amide bond forma
tion.

The resultant free carboxylic acid at the C-terminus is then
40

45

reacted in solution with molecules built from standard com

ponents for polyamides that recognize DNA, except that an
aliphatic beta-amino acid is not located immediately adjacent
to the C-terminal cationic group.
Suitable examples of C-terminal amines include the fol
lowing structures.
HN
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- Continued

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 6

Ctgctattitt ggalagattgg aat

23

SEO ID NO 7
LENGTH: 2O
TYPE: DNA

ORGANISM: Artificial
FEATURE:

OTHER INFORMATION: Primer

<4 OO > SEQUENCE: 7

ggcctgtgag gtgacaaacc
SEQ ID NO 8
LENGTH: 27
TYPE: DNA

ORGANISM: Artificial
FEATURE:

OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 8

ttggattgac cacacctic cc ticaggitt

27

What is claimed is:

1. A polyamide compound of the formula:

30

or a pharmaceutically acceptable salt thereof, wherein
m is 10 or 11;
n is 9 or 10;
Im is desamino-imidazole;

each X is independently selected from 4-amino-2-carbo
nyl-N-methylimidazole (I), 4-amino-2-carbonyl-N-me
thylpyrrole (P) or B-alanine (B), subject to the proviso
that the compound contains no more than two I units;
Y is Y-aminobutyric acid (Y), (S)-2,4-diaminobutyric acid,
(R)-2,4-diaminobutyric acid (Y), (S)-2-(acety
lamino)-4-aminobutyric acid, or (R)-2-(acetylamino)-4aminobutyric acid (Yv);
Yis B-alanine (B) or 4-amino-2-carbonyl-N-methylpyrrole
(P); and
A is 3,3'-diamino-N-methyldipropylamine (Ta) or dim
ethylaminopropylamine (Dp), with the proviso that the
polyamide compound is not
ImPPPBPPBPPPyPPPBPPPBPPPBDp,
ImPPPBPPBPPPYPPPBPPPBPPPBDp,
ImPPBPIPBPPYPPBPPPBPPPBTa,
ImPPBPIPBPPYPPBPPPBPPPBDp,
ImPPPPIPPPPIyPPPPPPPPPPBDp, ImPPPPPIPPPyPPP
PPPPPPPBDp, or
ImPPPPPPPPPPyPPPPPPPPPPPBDp.
2. A compound according to claim 1, wherein—(X) - is
selected from the group consisting of -PPBPPI BPP-, -PPB
PIPBPPI and -PPPBPPPBPP-.
3. A compound according to claim 1, wherein —(X) Y— is selected from the group consisting of -PPBPPPBP
PPB-, -(PBPPPBPPPB-, -PPPBPPPBPPPB-, and -PPBPPPB
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free of I units.
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PPPP

4. A compound according to claim 1, wherein—(X) - is
selected from the group consisting of -PPBPPI BPP-, -PPB
PIPBPPI-, and-PPPBPPPBPP-and-CX), Y is selected

from the group consisting of -PPBPPPBPPPB-, -(BPBPPPBP
PPB-, PPPBPPPBPPPB-, and-PPBPPPBPPPP
5. A compound according to claim 1, wherein Y is (R)-2,
4-diaminobutyric acid.
6. A compound according to claim 1, wherein Y is (R)-2,
4-diaminobutyric acid and the 2-amino group of the (R)-2,4diaminobutyric acid is incorporated into the polyamide via
the 2-amino group to provide an alpha turn.
7. A compound according to claim 1, wherein Y is (R)-2,
4-diaminobutyric acid and the 4-amino group of the (R)-2,4diaminobutyric acid is incorporated into the polyamide via
the 4-amino group to provide a gamma turn.
8. A compound according to claim 1, wherein —(X)- is
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9. A compound according to claim 1, wherein any B-ala
nine unit is adjacent to at least three contiguous units of
4-amino-2-carbonyl-N-methylpyrrole (P) unit, two contigu
ous units of 4-amino-carbonyl-N-methylimidazole (I), or at
least three contiguous units of any combination of 4-amino
2-carbonyl-N-methylpyrrole (P) units and 4-amino-carbo
nyl-N-methylimidazole (I) units.
10. A pharmaceutical composition, the pharmaceutical
composition comprising a pharmaceutically acceptable car
rier and at least one compound in accordance with claim 1.
11. A compound having formula:
ImPPBPPIBPPyPPBPPPBPPPBDp, ImPPBPPIBPPyPPBP
PPBPPPBTa;
ImPPBPIPBPPIyBPBPPPBPPPBTa: ImPPPBPPPBPPyPP
PBPPPBPPPBDp;
ImPPPBPPPBPPyPPPBPPPBPPPBTa;
ImPPBPPIBPPYPPBPPPBPPPBTa;
ImPPBPPIBPPYPPBPPPBPPPBDp;
ImPPBPPIBPPYPPBPPPBPPPBDp;
ImPPBPPIBPPYPPBPPPBPPPBTa:
ImPPBPPIB
PPYPPBPPPBPPPBDp;
ImPPBPPIBPPyPPBPPPBPPPPTa; or ImPPBPPPyPPBPP
PPPTa;

or a pharmaceutically acceptable salt thereof;
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wherein:

Im is desamino-imidazole;

P is 4-amino-2-carbonyl-N-methylpyrrole;
B is B-alanine;

I is 4-amino-2-carbonyl-N-methylimidazole;

5

Y is Y-aminobutyric acid,
Y is (R)-2,4-diaminobutyric acid reacted through either
the 2-amino group or the 4-amino group;
Y is (R)-2-(acetylamino)-4-aminobutyric acid;
Ta is 3,3'-diamino-N-methyldipropylamine; and

10

Dp is dimethylaminopropylamine.
12. A pharmaceutical composition, the pharmaceutical
composition comprising a pharmaceutically acceptable car
rier and a compound in accordance with claim 11.
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